A Phase 2 interventional study of Niraparib and Carboplatin in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Terminated at 21 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.
Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 26th largest by enrollment, is one of 2 that started in 2022, is one of 18 in phase 2, and was the 44th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
University of Miami · Sites in United States, Nigeria
Ages 18+ · Women only
MedSIR · Sites in Spain
Ages 18+ · Women only
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+ · Women only
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Women only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Women only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 22 · Phase 3 7 · Phase 4 5
First in 2008; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 41 across the 44 interventional studies. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tesaro, Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Tesaro, Inc. is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
31 studies in Ovarian Neoplasms by GlaxoSmithKline: 5 open now, 7 under way, 5 of them phase 3. Of 22 finished, 16 (73%) have results posted.
Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 23rd largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2022, is one of 15 in phase 2, and was the 28th registered.
GlaxoSmithKline’s Ovarian Neoplasms studies by the year they started, since 1997.
2 of the studies testing niraparib in Ovarian Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04641247GlaxoSmithKlineA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | 2026-12-28 |
| NCT06594679Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoA Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) | 2027-03-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing niraparib in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 31 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must provide sufficient tumor tissue at Prescreening and agree to undergo a central HRD tumor testing using a fully validated assay. The participants must be HRd as per central HRD tumor testing result for eligibility.
Exclusion Criteria:
Participant is . Participants with splenectomy are allowed. Participants with known (HIV) are allowed if they meet all of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Niraparib
Drug: Carboplatin · Drug: Paclitaxel
Niraparib will be administered
Carboplatin will be administered
Paclitaxel will be administered
Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR)
Pre-IDS unconfirmed ORR is defined as the percentage of participants with unconfirmed complete or partial response on study treatment pre-IDS as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters
Time frame: Up to approximately 102 weeks
Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria
Serum samples were collected to assess CA-125 progression based on the GCIG CA-125 response criteria, which is defined as follows: Criteria 1 - For participants with elevated CA-125 levels pre-treatment that reduced to the normal range during the study, progression is defined as CA-125 ≥2× Upper limit of normal (ULN) on 2 occasions at least 1 week apart.; Criteria 2 - For participants with elevated CA-125 levels pre-treatment that did not reduce to the normal range during the study, progression is defined as CA-125 ≥2× the nadir value on 2 occasions at least 1 week apart.; Criteria 3 - For participants with CA-125 levels in the normal range pre-treatment, progression is defined as CA-125 ≥2× ULN on 2 occasions at least 1 week apart.
Time frame: At week 24
Progression Free Survival (PFS)
PFS is defined as the time from the date of treatment randomization to the date of first documentation of disease progression (PD) per RECIST v1.1 or death by any cause, whichever occurs first, as determined by the Investigator. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Time frame: Up to approximately 154 weeks
Overall Survival (OS)
OS is defined as the time from the date of treatment randomization to the date of death by any cause.
Time frame: Up to approximately 154 weeks
Time to First Subsequent Treatment (TFST)
TFST is defined as the time from the date of treatment randomization to the date of first subsequent anticancer therapy or death.
Time frame: Up to approximately 154 weeks
Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants of cancer clinical studies. It characterizes the frequency and severity of adverse events using a standardized scoring system. Responses include 0 ("never" OR "none" OR "Not at all"); 1 ("Rarely" OR "Mild" OR "A little bit"); 2 ("Occasionally" OR "Moderate" OR "Somewhat"); 3 ("Frequently" OR "Severe" OR "Quite a bit") and 4 ("almost constantly" OR "very severe" OR "Very much"), with a higher score indicating a higher frequency and severity of adverse events.
Time frame: Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8 and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5
The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for participants with cancer. It evaluates the extent to which side effects of treatment are bothersome for cancer participants. This outcome is measured using a 5-category response scale, where responses include 0="Not at all," 1="A little bit," 2="Somewhat," 3="Quite a bit," and 4="Very much." A higher score on this measure indicates that the participant experiences a greater level of bother from the side effects of treatment.
Time frame: Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8, and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks)
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire
EORTC IL136 includes items from the EORTC QLQ-C30, a 30-item survey assessing health-related quality of life (HRQoL) in cancer patients, featuring 5 functional scales, 3 symptom scales, 6 single items, and a global health status/HRQoL scale. Functional and symptom scales/items are rated on 4-point scale with options "Not at all," "A little," "Quite a bit," and "Very much". 2 items measuring global health status/quality of life use a 7-point scale ranging from 1 ("Very Poor") to 7 ("Excellent"). Each item has a specific scoring system, and scores were transformed to a 0-100 scale, where higher scores on functional scales and global health status/HRQoL scale indicate better functioning or quality of life, while higher scores on symptom scales/items indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to Cycle 1 Day 1 (C1D1), including those from unscheduled visits.
Time frame: Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire
The OC module (QLQ-OV28) supplements the QLQ-C30 and was designed for participants with local or advanced disease who receive treatment by surgery with or without chemotherapy. It consists of 28 items including 3 functional scales (body image, sexuality, attitude to disease/treatment burden) and 5 symptom scales/items (abdominal/gastrointestinal symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side effects, and hair loss). A subset of 9 questions will be utilized for this cohort, referred to as the EORTC IL137. The scoring approach is identical to the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, where higher functional scale scores indicate better functioning, and higher symptom scale scores indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to C1D1, including unscheduled visits.
Time frame: Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: Up to approximately 154 weeks
Number of Participants With Dose Modification Due to TEAEs
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with dose modifications : permanent discontinuation, dose reduction and treatment interruption/delay due to AEs is summarized.
Time frame: Up to approximately 154 weeks
| Milestone | Platinum-taxane | Niraparib |
|---|---|---|
| Started | 17 | 19 |
| Completed | 0 | 0 |
| Not completed | 17 | 19 |
| Withdrew: Death | 4 | 4 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Study terminated by sponsor | 12 | 10 |
| Withdrew: Participant discontinued due to relocation to a long-term care facility | 0 | 1 |
| Withdrew: Participant removed due to non-compliance | 0 | 1 |
Pre-IDS unconfirmed ORR is defined as the percentage of participants with unconfirmed complete or partial response on study treatment pre-IDS as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters
| Percentage of Participants | Platinum-taxane | Niraparib |
|---|---|---|
| Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR) | 70.6 (44.04 to 89.69) | 31.6 (16.34 to 67.71) |
Serum samples were collected to assess CA-125 progression based on the GCIG CA-125 response criteria, which is defined as follows: Criteria 1 - For participants with elevated CA-125 levels pre-treatment that reduced to the normal range during the study, progression is defined as CA-125 ≥2× Upper limit of normal (ULN) on 2 occasions at least 1 week apart.; Criteria 2 - For participants with elevated CA-125 levels pre-treatment that did not reduce to the normal range during the study, progression is defined as CA-125 ≥2× the nadir value on 2 occasions at least 1 week apart.; Criteria 3 - For participants with CA-125 levels in the normal range pre-treatment, progression is defined as CA-125 ≥2× ULN on 2 occasions at least 1 week apart.
| Participants | Platinum-taxane | Niraparib |
|---|---|---|
| Criteria 1 | 0 | 0 |
| Criteria 2 | 0 | 0 |
| Criteria 3 | 0 | 0 |
PFS is defined as the time from the date of treatment randomization to the date of first documentation of disease progression (PD) per RECIST v1.1 or death by any cause, whichever occurs first, as determined by the Investigator. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
No measurements were reported for this outcome.
OS is defined as the time from the date of treatment randomization to the date of death by any cause.
No measurements were reported for this outcome.
TFST is defined as the time from the date of treatment randomization to the date of first subsequent anticancer therapy or death.
No measurements were reported for this outcome.
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants of cancer clinical studies. It characterizes the frequency and severity of adverse events using a standardized scoring system. Responses include 0 ("never" OR "none" OR "Not at all"); 1 ("Rarely" OR "Mild" OR "A little bit"); 2 ("Occasionally" OR "Moderate" OR "Somewhat"); 3 ("Frequently" OR "Severe" OR "Quite a bit") and 4 ("almost constantly" OR "very severe" OR "Very much"), with a higher score indicating a higher frequency and severity of adverse events.
| Participants | Platinum-taxane | Niraparib |
|---|---|---|
| Probs Tasting Food/Drink, Baseline, Severity, 0=None | 10 | 9 |
| Probs Tasting Food/Drink, Baseline, Severity, 1=Mild | 3 | 4 |
| Probs Tasting Food/Drink, Baseline, Severity, 2=Moderate | 1 | 3 |
| Probs Tasting Food/Drink, Baseline, Severity, 3=Severe | 0 | 1 |
| Probs Tasting Food/Drink, Baseline, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 0=None | 6 | 7 |
| Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 1=Mild | 3 | 5 |
| Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 2=Moderate | 2 | 2 |
| Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 3=Severe | 0 | 1 |
| Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 0=None | 12 | 6 |
| Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 1=Mild | 1 | 5 |
| Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 2=Moderate | 1 | 2 |
| Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 3=Severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 0=None | 9 | 8 |
| Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 1=Mild | 2 | 4 |
| Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 2=Moderate | 0 | 1 |
| Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 3=Severe | 0 | 1 |
| Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 0=None | 6 | 6 |
| Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 1=Mild | 3 | 4 |
| Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 2=Moderate | 1 | 0 |
| Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 3=Severe | 1 | 1 |
| Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 0=None | 8 | 10 |
| Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 1=Mild | 5 | 3 |
| Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 2=Moderate | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 0=None | 12 | 8 |
| Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 1=Mild | 2 | 4 |
| Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 2=Moderate | 0 | 1 |
| Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 3=Severe | 0 | 1 |
| Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 0=None | 1 | 6 |
| Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 1=Mild | 3 | 3 |
| Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 2=Moderate | 4 | 0 |
| Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 3=Severe | 2 | 1 |
| Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 0=None | 3 | 4 |
| Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 1=Mild | 2 | 3 |
| Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 2=Moderate | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 0=None | 1 | 0 |
| Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 1=Mild | 1 | 1 |
| Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | 0 |
| Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 3=Severe | 0 | 0 |
| Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | 0 |
| Probs Tasting Food/Drink, End Of Treatment, Severity, 0=None | — | 2 |
| Probs Tasting Food/Drink, End Of Treatment, Severity, 1=Mild | — | 3 |
| Probs Tasting Food/Drink, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Probs Tasting Food/Drink, End Of Treatment, Severity, 3=Severe | — | 0 |
| Probs Tasting Food/Drink, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Nausea, Baseline, Severity, 0=None | 1 | 2 |
| Nausea, Baseline, Severity, 1=Mild | 5 | 5 |
| Nausea, Baseline, Severity, 2=Moderate | 1 | 1 |
| Nausea, Baseline, Severity, 3=Severe | 0 | 0 |
| Nausea, Baseline, Severity, 4=Very severe | 0 | 1 |
| Nausea, Baseline, Frequency, 0=Never | 7 | 8 |
| Nausea, Baseline, Frequency, 1=Rarely | 6 | 5 |
| Nausea, Baseline, Frequency, 2=Occasionally | 1 | 4 |
| Nausea, Baseline, Frequency, 3=Frequently | 0 | 0 |
| Nausea, Baseline, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, Cycle 1 Day 8, Severity, 0=None | 1 | 0 |
| Nausea, Cycle 1 Day 8, Severity, 1=Mild | 3 | 2 |
| Nausea, Cycle 1 Day 8, Severity, 2=Moderate | 5 | 3 |
| Nausea, Cycle 1 Day 8, Severity, 3=Severe | 0 | 2 |
| Nausea, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 1 Day 8, Frequency, 0=Never | 2 | 8 |
| Nausea, Cycle 1 Day 8, Frequency, 1=Rarely | 4 | 2 |
| Nausea, Cycle 1 Day 8, Frequency, 2=Occasionally | 4 | 3 |
| Nausea, Cycle 1 Day 8, Frequency, 3=Frequently | 1 | 1 |
| Nausea, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 | 1 |
| Nausea, Cycle 1 Day 15, Severity, 0=None | 1 | 0 |
| Nausea, Cycle 1 Day 15, Severity, 1=Mild | 3 | 2 |
| Nausea, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 3 |
| Nausea, Cycle 1 Day 15, Severity, 3=Severe | 0 | 1 |
| Nausea, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 1 Day 15, Frequency, 0=Never | 8 | 7 |
| Nausea, Cycle 1 Day 15, Frequency, 1=Rarely | 3 | 2 |
| Nausea, Cycle 1 Day 15, Frequency, 2=Occasionally | 3 | 3 |
| Nausea, Cycle 1 Day 15, Frequency, 3=Frequently | 0 | 1 |
| Nausea, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, Cycle 2 Day 1, Severity, 0=None | 1 | 1 |
| Nausea, Cycle 2 Day 1, Severity, 1=Mild | 0 | 3 |
| Nausea, Cycle 2 Day 1, Severity, 2=Moderate | 1 | 1 |
| Nausea, Cycle 2 Day 1, Severity, 3=Severe | 0 | 2 |
| Nausea, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 2 Day 1, Frequency, 0=Never | 9 | 7 |
| Nausea, Cycle 2 Day 1, Frequency, 1=Rarely | 2 | 3 |
| Nausea, Cycle 2 Day 1, Frequency, 2=Occasionally | 0 | 3 |
| Nausea, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 0 |
| Nausea, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 1 |
| Nausea, Cycle 2 Day 8, Severity, 0=None | 1 | 2 |
| Nausea, Cycle 2 Day 8, Severity, 1=Mild | 4 | 1 |
| Nausea, Cycle 2 Day 8, Severity, 2=Moderate | 0 | 1 |
| Nausea, Cycle 2 Day 8, Severity, 3=Severe | 0 | 1 |
| Nausea, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 2 Day 8, Frequency, 0=Never | 6 | 6 |
| Nausea, Cycle 2 Day 8, Frequency, 1=Rarely | 3 | 3 |
| Nausea, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 | 1 |
| Nausea, Cycle 2 Day 8, Frequency, 3=Frequently | 0 | 1 |
| Nausea, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, Cycle 2 Day 15, Severity, 0=None | 0 | 2 |
| Nausea, Cycle 2 Day 15, Severity, 1=Mild | 2 | 1 |
| Nausea, Cycle 2 Day 15, Severity, 2=Moderate | 0 | 2 |
| Nausea, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Nausea, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 2 Day 15, Frequency, 0=Never | 11 | 8 |
| Nausea, Cycle 2 Day 15, Frequency, 1=Rarely | 1 | 3 |
| Nausea, Cycle 2 Day 15, Frequency, 2=Occasionally | 1 | 1 |
| Nausea, Cycle 2 Day 15, Frequency, 3=Frequently | 0 | 2 |
| Nausea, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, Cycle 3 Day 1, Severity, 0=None | 0 | 0 |
| Nausea, Cycle 3 Day 1, Severity, 1=Mild | 2 | 3 |
| Nausea, Cycle 3 Day 1, Severity, 2=Moderate | 0 | 1 |
| Nausea, Cycle 3 Day 1, Severity, 3=Severe | 0 | 1 |
| Nausea, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 1 |
| Nausea, Cycle 3 Day 1, Frequency, 0=Never | 12 | 8 |
| Nausea, Cycle 3 Day 1, Frequency, 1=Rarely | 2 | 3 |
| Nausea, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 | 0 |
| Nausea, Cycle 3 Day 1, Frequency, 3=Frequently | 0 | 2 |
| Nausea, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 | 1 |
| Nausea, Cycle 3 Day 8, Severity, 0=None | 1 | 1 |
| Nausea, Cycle 3 Day 8, Severity, 1=Mild | 1 | 2 |
| Nausea, Cycle 3 Day 8, Severity, 2=Moderate | 2 | 1 |
| Nausea, Cycle 3 Day 8, Severity, 3=Severe | 1 | 1 |
| Nausea, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 3 Day 8, Frequency, 0=Never | 5 | 5 |
| Nausea, Cycle 3 Day 8, Frequency, 1=Rarely | 2 | 2 |
| Nausea, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 | 2 |
| Nausea, Cycle 3 Day 8, Frequency, 3=Frequently | 3 | 1 |
| Nausea, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, Cycle 3 Day 15, Severity, 0=None | 0 | 2 |
| Nausea, Cycle 3 Day 15, Severity, 1=Mild | 3 | 0 |
| Nausea, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 1 |
| Nausea, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Nausea, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Nausea, Cycle 3 Day 15, Frequency, 0=Never | 1 | 4 |
| Nausea, Cycle 3 Day 15, Frequency, 1=Rarely | 3 | 2 |
| Nausea, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 | 1 |
| Nausea, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Nausea, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 1 |
| Nausea, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Nausea, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Nausea, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Nausea, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Nausea, End Of Treatment, Severity, 0=None | — | 1 |
| Nausea, End Of Treatment, Severity, 1=Mild | — | 3 |
| Nausea, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Nausea, End Of Treatment, Severity, 3=Severe | — | 0 |
| Nausea, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Nausea, End Of Treatment, Frequency, 0=Never | — | 1 |
| Nausea, End Of Treatment, Frequency, 1=Rarely | — | 3 |
| Nausea, End Of Treatment, Frequency, 2=Occasionally | — | 1 |
| Nausea, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Nausea, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Vomiting, Baseline, Severity, 0=None | 0 | 0 |
| Vomiting, Baseline, Severity, 1=Mild | 1 | 0 |
| Vomiting, Baseline, Severity, 2=Moderate | 0 | 1 |
| Vomiting, Baseline, Severity, 3=Severe | 0 | 0 |
| Vomiting, Baseline, Severity, 4=Very severe | 0 | 0 |
| Vomiting, Baseline, Frequency, 0=Never | 13 | 16 |
| Vomiting, Baseline, Frequency, 1=Rarely | 1 | 0 |
| Vomiting, Baseline, Frequency, 2=Occasionally | 0 | 1 |
| Vomiting, Baseline, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Baseline, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 1 Day 8, Severity, 0=None | 0 | 0 |
| Vomiting, Cycle 1 Day 8, Severity, 1=Mild | 1 | 2 |
| Vomiting, Cycle 1 Day 8, Severity, 2=Moderate | 0 | 1 |
| Vomiting, Cycle 1 Day 8, Severity, 3=Severe | 0 | 0 |
| Vomiting, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Vomiting, Cycle 1 Day 8, Frequency, 0=Never | 10 | 12 |
| Vomiting, Cycle 1 Day 8, Frequency, 1=Rarely | 1 | 2 |
| Vomiting, Cycle 1 Day 8, Frequency, 2=Occasionally | 0 | 1 |
| Vomiting, Cycle 1 Day 8, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 1 Day 15, Severity, 0=None | — | 0 |
| Vomiting, Cycle 1 Day 15, Severity, 1=Mild | — | 1 |
| Vomiting, Cycle 1 Day 15, Severity, 2=Moderate | — | 0 |
| Vomiting, Cycle 1 Day 15, Severity, 3=Severe | — | 0 |
| Vomiting, Cycle 1 Day 15, Severity, 4=Very severe | — | 0 |
| Vomiting, Cycle 1 Day 15, Frequency, 0=Never | 14 | 12 |
| Vomiting, Cycle 1 Day 15, Frequency, 1=Rarely | 0 | 1 |
| Vomiting, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 | 0 |
| Vomiting, Cycle 1 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 2 Day 1, Severity, 0=None | — | 0 |
| Vomiting, Cycle 2 Day 1, Severity, 1=Mild | — | 1 |
| Vomiting, Cycle 2 Day 1, Severity, 2=Moderate | — | 1 |
| Vomiting, Cycle 2 Day 1, Severity, 3=Severe | — | 0 |
| Vomiting, Cycle 2 Day 1, Severity, 4=Very severe | — | 0 |
| Vomiting, Cycle 2 Day 1, Frequency, 0=Never | 11 | 12 |
| Vomiting, Cycle 2 Day 1, Frequency, 1=Rarely | 0 | 2 |
| Vomiting, Cycle 2 Day 1, Frequency, 2=Occasionally | 0 | 0 |
| Vomiting, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 2 Day 8, Severity, 0=None | 0 | 0 |
| Vomiting, Cycle 2 Day 8, Severity, 1=Mild | 1 | 1 |
| Vomiting, Cycle 2 Day 8, Severity, 2=Moderate | 0 | 1 |
| Vomiting, Cycle 2 Day 8, Severity, 3=Severe | 0 | 0 |
| Vomiting, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Vomiting, Cycle 2 Day 8, Frequency, 0=Never | 10 | 9 |
| Vomiting, Cycle 2 Day 8, Frequency, 1=Rarely | 1 | 2 |
| Vomiting, Cycle 2 Day 8, Frequency, 2=Occasionally | 0 | 0 |
| Vomiting, Cycle 2 Day 8, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 2 Day 15, Severity, 0=None | 0 | 1 |
| Vomiting, Cycle 2 Day 15, Severity, 1=Mild | 1 | 0 |
| Vomiting, Cycle 2 Day 15, Severity, 2=Moderate | 0 | 0 |
| Vomiting, Cycle 2 Day 15, Severity, 3=Severe | 0 | 0 |
| Vomiting, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Vomiting, Cycle 2 Day 15, Frequency, 0=Never | 12 | 13 |
| Vomiting, Cycle 2 Day 15, Frequency, 1=Rarely | 1 | 1 |
| Vomiting, Cycle 2 Day 15, Frequency, 2=Occasionally | 0 | 0 |
| Vomiting, Cycle 2 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 3 Day 1, Severity, 0=None | — | 0 |
| Vomiting, Cycle 3 Day 1, Severity, 1=Mild | — | 1 |
| Vomiting, Cycle 3 Day 1, Severity, 2=Moderate | — | 0 |
| Vomiting, Cycle 3 Day 1, Severity, 3=Severe | — | 2 |
| Vomiting, Cycle 3 Day 1, Severity, 4=Very severe | — | 0 |
| Vomiting, Cycle 3 Day 1, Frequency, 0=Never | 14 | 11 |
| Vomiting, Cycle 3 Day 1, Frequency, 1=Rarely | 0 | 2 |
| Vomiting, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 | 0 |
| Vomiting, Cycle 3 Day 1, Frequency, 3=Frequently | 0 | 1 |
| Vomiting, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Severity, 0=None | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Severity, 1=Mild | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Severity, 2=Moderate | 1 | 1 |
| Vomiting, Cycle 3 Day 8, Severity, 3=Severe | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Frequency, 0=Never | 9 | 9 |
| Vomiting, Cycle 3 Day 8, Frequency, 1=Rarely | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Frequency, 2=Occasionally | 1 | 1 |
| Vomiting, Cycle 3 Day 8, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Cycle 3 Day 15, Severity, 0=None | — | 1 |
| Vomiting, Cycle 3 Day 15, Severity, 1=Mild | — | 0 |
| Vomiting, Cycle 3 Day 15, Severity, 2=Moderate | — | 1 |
| Vomiting, Cycle 3 Day 15, Severity, 3=Severe | — | 0 |
| Vomiting, Cycle 3 Day 15, Severity, 4=Very severe | — | 0 |
| Vomiting, Cycle 3 Day 15, Frequency, 0=Never | 5 | 5 |
| Vomiting, Cycle 3 Day 15, Frequency, 1=Rarely | 0 | 1 |
| Vomiting, Cycle 3 Day 15, Frequency, 2=Occasionally | 0 | 1 |
| Vomiting, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 1 |
| Vomiting, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Vomiting, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Vomiting, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Vomiting, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Vomiting, End Of Treatment, Severity, 0=None | — | 0 |
| Vomiting, End Of Treatment, Severity, 1=Mild | — | 1 |
| Vomiting, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Vomiting, End Of Treatment, Severity, 3=Severe | — | 0 |
| Vomiting, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Vomiting, End Of Treatment, Frequency, 0=Never | — | 4 |
| Vomiting, End Of Treatment, Frequency, 1=Rarely | — | 0 |
| Vomiting, End Of Treatment, Frequency, 2=Occasionally | — | 1 |
| Vomiting, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Vomiting, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Bloating of Abdomen, Baseline, Severity, 0=None | 0 | 0 |
| Bloating of Abdomen, Baseline, Severity, 1=Mild | 7 | 5 |
| Bloating of Abdomen, Baseline, Severity, 2=Moderate | 3 | 3 |
| Bloating of Abdomen, Baseline, Severity, 3=Severe | 1 | 0 |
| Bloating of Abdomen, Baseline, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Baseline, Frequency, 0=Never | 3 | 9 |
| Bloating of Abdomen, Baseline, Frequency, 1=Rarely | 5 | 3 |
| Bloating of Abdomen, Baseline, Frequency, 2=Occasionally | 3 | 4 |
| Bloating of Abdomen, Baseline, Frequency, 3=Frequently | 1 | 1 |
| Bloating of Abdomen, Baseline, Frequency, 4=Almost constantly | 2 | 0 |
| Bloating of Abdomen, Cycle 1 Day 8, Severity, 0=None | 0 | 0 |
| Bloating of Abdomen, Cycle 1 Day 8, Severity, 1=Mild | 3 | 5 |
| Bloating of Abdomen, Cycle 1 Day 8, Severity, 2=Moderate | 4 | 3 |
| Bloating of Abdomen, Cycle 1 Day 8, Severity, 3=Severe | 1 | 1 |
| Bloating of Abdomen, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 1 Day 8, Frequency, 0=Never | 3 | 6 |
| Bloating of Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely | 1 | 3 |
| Bloating of Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally | 5 | 4 |
| Bloating of Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently | 1 | 0 |
| Bloating of Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 | 2 |
| Bloating of Abdomen, Cycle 1 Day 15, Severity, 0=None | 0 | 0 |
| Bloating of Abdomen, Cycle 1 Day 15, Severity, 1=Mild | 5 | 2 |
| Bloating of Abdomen, Cycle 1 Day 15, Severity, 2=Moderate | 3 | 5 |
| Bloating of Abdomen, Cycle 1 Day 15, Severity, 3=Severe | 0 | 1 |
| Bloating of Abdomen, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 1 |
| Bloating of Abdomen, Cycle 1 Day 15, Frequency, 0=Never | 6 | 4 |
| Bloating of Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely | 5 | 3 |
| Bloating of Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 | 4 |
| Bloating of Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently | 2 | 0 |
| Bloating of Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 | 2 |
| Bloating of Abdomen, Cycle 2 Day 1, Severity, 0=None | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 1, Severity, 1=Mild | 7 | 3 |
| Bloating of Abdomen, Cycle 2 Day 1, Severity, 2=Moderate | 0 | 3 |
| Bloating of Abdomen, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 1, Frequency, 0=Never | 4 | 8 |
| Bloating of Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely | 6 | 3 |
| Bloating of Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 | 3 |
| Bloating of Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 8, Severity, 0=None | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 8, Severity, 1=Mild | 4 | 4 |
| Bloating of Abdomen, Cycle 2 Day 8, Severity, 2=Moderate | 2 | 3 |
| Bloating of Abdomen, Cycle 2 Day 8, Severity, 3=Severe | 2 | 0 |
| Bloating of Abdomen, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 8, Frequency, 0=Never | 3 | 4 |
| Bloating of Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely | 3 | 4 |
| Bloating of Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally | 3 | 2 |
| Bloating of Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently | 2 | 1 |
| Bloating of Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 15, Severity, 0=None | 0 | 1 |
| Bloating of Abdomen, Cycle 2 Day 15, Severity, 1=Mild | 5 | 3 |
| Bloating of Abdomen, Cycle 2 Day 15, Severity, 2=Moderate | 2 | 2 |
| Bloating of Abdomen, Cycle 2 Day 15, Severity, 3=Severe | 0 | 3 |
| Bloating of Abdomen, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 2 Day 15, Frequency, 0=Never | 6 | 5 |
| Bloating of Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely | 2 | 4 |
| Bloating of Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally | 4 | 1 |
| Bloating of Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently | 1 | 4 |
| Bloating of Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Bloating of Abdomen, Cycle 3 Day 1, Severity, 0=None | 1 | 0 |
| Bloating of Abdomen, Cycle 3 Day 1, Severity, 1=Mild | 4 | 6 |
| Bloating of Abdomen, Cycle 3 Day 1, Severity, 2=Moderate | 2 | 3 |
| Bloating of Abdomen, Cycle 3 Day 1, Severity, 3=Severe | 0 | 1 |
| Bloating of Abdomen, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 3 Day 1, Frequency, 0=Never | 7 | 4 |
| Bloating of Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely | 2 | 5 |
| Bloating of Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally | 2 | 4 |
| Bloating of Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently | 3 | 1 |
| Bloating of Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Bloating of Abdomen, Cycle 3 Day 8, Severity, 0=None | 1 | 0 |
| Bloating of Abdomen, Cycle 3 Day 8, Severity, 1=Mild | 2 | 5 |
| Bloating of Abdomen, Cycle 3 Day 8, Severity, 2=Moderate | 2 | 3 |
| Bloating of Abdomen, Cycle 3 Day 8, Severity, 3=Severe | 1 | 1 |
| Bloating of Abdomen, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 3 Day 8, Frequency, 0=Never | 4 | 1 |
| Bloating of Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely | 2 | 4 |
| Bloating of Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally | 3 | 3 |
| Bloating of Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently | 0 | 2 |
| Bloating of Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Bloating of Abdomen, Cycle 3 Day 15, Severity, 0=None | 1 | 0 |
| Bloating of Abdomen, Cycle 3 Day 15, Severity, 1=Mild | 1 | 3 |
| Bloating of Abdomen, Cycle 3 Day 15, Severity, 2=Moderate | 0 | 2 |
| Bloating of Abdomen, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Bloating of Abdomen, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Bloating of Abdomen, Cycle 3 Day 15, Frequency, 0=Never | 3 | 2 |
| Bloating of Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely | 1 | 3 |
| Bloating of Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 | 0 |
| Bloating of Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 2 |
| Bloating of Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 1 |
| Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Bloating of Abdomen, End Of Treatment, Severity, 0=None | — | 0 |
| Bloating of Abdomen, End Of Treatment, Severity, 1=Mild | — | 2 |
| Bloating of Abdomen, End Of Treatment, Severity, 2=Moderate | — | 1 |
| Bloating of Abdomen, End Of Treatment, Severity, 3=Severe | — | 1 |
| Bloating of Abdomen, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Bloating of Abdomen, End Of Treatment, Frequency, 0=Never | — | 1 |
| Bloating of Abdomen, End Of Treatment, Frequency, 1=Rarely | — | 1 |
| Bloating of Abdomen, End Of Treatment, Frequency, 2=Occasionally | — | 1 |
| Bloating of Abdomen, End Of Treatment, Frequency, 3=Frequently | — | 1 |
| Bloating of Abdomen, End Of Treatment, Frequency, 4=Almost constantly | — | 1 |
| Constipation, Baseline, Severity, 0=None | 8 | 9 |
| Constipation, Baseline, Severity, 1=Mild | 3 | 6 |
| Constipation, Baseline, Severity, 2=Moderate | 1 | 2 |
| Constipation, Baseline, Severity, 3=Severe | 1 | 0 |
| Constipation, Baseline, Severity, 4=Very severe | 1 | 0 |
| Constipation, Cycle 1 Day 8, Severity, 0=None | 5 | 8 |
| Constipation, Cycle 1 Day 8, Severity, 1=Mild | 0 | 2 |
| Constipation, Cycle 1 Day 8, Severity, 2=Moderate | 3 | 2 |
| Constipation, Cycle 1 Day 8, Severity, 3=Severe | 3 | 3 |
| Constipation, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Constipation, Cycle 1 Day 15, Severity, 0=None | 10 | 6 |
| Constipation, Cycle 1 Day 15, Severity, 1=Mild | 4 | 4 |
| Constipation, Cycle 1 Day 15, Severity, 2=Moderate | 0 | 1 |
| Constipation, Cycle 1 Day 15, Severity, 3=Severe | 0 | 1 |
| Constipation, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 1 |
| Constipation, Cycle 2 Day 1, Severity, 0=None | 8 | 6 |
| Constipation, Cycle 2 Day 1, Severity, 1=Mild | 2 | 5 |
| Constipation, Cycle 2 Day 1, Severity, 2=Moderate | 1 | 2 |
| Constipation, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Constipation, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 1 |
| Constipation, Cycle 2 Day 8, Severity, 0=None | 6 | 5 |
| Constipation, Cycle 2 Day 8, Severity, 1=Mild | 2 | 4 |
| Constipation, Cycle 2 Day 8, Severity, 2=Moderate | 2 | 2 |
| Constipation, Cycle 2 Day 8, Severity, 3=Severe | 1 | 0 |
| Constipation, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Constipation, Cycle 2 Day 15, Severity, 0=None | 10 | 8 |
| Constipation, Cycle 2 Day 15, Severity, 1=Mild | 3 | 2 |
| Constipation, Cycle 2 Day 15, Severity, 2=Moderate | 0 | 3 |
| Constipation, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Constipation, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Constipation, Cycle 3 Day 1, Severity, 0=None | 11 | 6 |
| Constipation, Cycle 3 Day 1, Severity, 1=Mild | 2 | 1 |
| Constipation, Cycle 3 Day 1, Severity, 2=Moderate | 1 | 5 |
| Constipation, Cycle 3 Day 1, Severity, 3=Severe | 0 | 1 |
| Constipation, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 1 |
| Constipation, Cycle 3 Day 8, Severity, 0=None | 4 | 4 |
| Constipation, Cycle 3 Day 8, Severity, 1=Mild | 5 | 2 |
| Constipation, Cycle 3 Day 8, Severity, 2=Moderate | 1 | 2 |
| Constipation, Cycle 3 Day 8, Severity, 3=Severe | 0 | 2 |
| Constipation, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Constipation, Cycle 3 Day 15, Severity, 0=None | 4 | 3 |
| Constipation, Cycle 3 Day 15, Severity, 1=Mild | 1 | 3 |
| Constipation, Cycle 3 Day 15, Severity, 2=Moderate | 0 | 1 |
| Constipation, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Constipation, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Constipation, Pre-IDS Evaluation, Severity, 0=None | 2 | 0 |
| Constipation, Pre-IDS Evaluation, Severity, 1=Mild | 0 | 0 |
| Constipation, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | 0 |
| Constipation, Pre-IDS Evaluation, Severity, 3=Severe | 0 | 0 |
| Constipation, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | 1 |
| Constipation, End Of Treatment, Severity, 0=None | — | 2 |
| Constipation, End Of Treatment, Severity, 1=Mild | — | 3 |
| Constipation, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Constipation, End Of Treatment, Severity, 3=Severe | — | 0 |
| Constipation, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Loose/Watery Stools, Baseline, Frequency, 0=Never | 8 | 10 |
| Loose/Watery Stools, Baseline, Frequency, 1=Rarely | 2 | 5 |
| Loose/Watery Stools, Baseline, Frequency, 2=Occasionally | 4 | 1 |
| Loose/Watery Stools, Baseline, Frequency, 3=Frequently | 0 | 1 |
| Loose/Watery Stools, Baseline, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Cycle 1 Day 8, Frequency, 0=Never | 8 | 11 |
| Loose/Watery Stools, Cycle 1 Day 8, Frequency, 1=Rarely | 1 | 3 |
| Loose/Watery Stools, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 | 1 |
| Loose/Watery Stools, Cycle 1 Day 8, Frequency, 3=Frequently | 0 | 0 |
| Loose/Watery Stools, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Cycle 1 Day 15, Frequency, 0=Never | 11 | 10 |
| Loose/Watery Stools, Cycle 1 Day 15, Frequency, 1=Rarely | 2 | 2 |
| Loose/Watery Stools, Cycle 1 Day 15, Frequency, 2=Occasionally | 1 | 1 |
| Loose/Watery Stools, Cycle 1 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Loose/Watery Stools, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Cycle 2 Day 1, Frequency, 0=Never | 9 | 12 |
| Loose/Watery Stools, Cycle 2 Day 1, Frequency, 1=Rarely | 0 | 1 |
| Loose/Watery Stools, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 | 0 |
| Loose/Watery Stools, Cycle 2 Day 1, Frequency, 3=Frequently | 1 | 1 |
| Loose/Watery Stools, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Cycle 2 Day 8, Frequency, 0=Never | 7 | 9 |
| Loose/Watery Stools, Cycle 2 Day 8, Frequency, 1=Rarely | 2 | 2 |
| Loose/Watery Stools, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 | 0 |
| Loose/Watery Stools, Cycle 2 Day 8, Frequency, 3=Frequently | 0 | 0 |
| Loose/Watery Stools, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Cycle 2 Day 15, Frequency, 0=Never | 8 | 12 |
| Loose/Watery Stools, Cycle 2 Day 15, Frequency, 1=Rarely | 1 | 1 |
| Loose/Watery Stools, Cycle 2 Day 15, Frequency, 2=Occasionally | 3 | 1 |
| Loose/Watery Stools, Cycle 2 Day 15, Frequency, 3=Frequently | 1 | 0 |
| Loose/Watery Stools, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Cycle 3 Day 1, Frequency, 0=Never | 8 | 12 |
| Loose/Watery Stools, Cycle 3 Day 1, Frequency, 1=Rarely | 4 | 1 |
| Loose/Watery Stools, Cycle 3 Day 1, Frequency, 2=Occasionally | 0 | 1 |
| Loose/Watery Stools, Cycle 3 Day 1, Frequency, 3=Frequently | 1 | 0 |
| Loose/Watery Stools, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 | 0 |
| Loose/Watery Stools, Cycle 3 Day 8, Frequency, 0=Never | 7 | 8 |
| Loose/Watery Stools, Cycle 3 Day 8, Frequency, 1=Rarely | 0 | 1 |
| Loose/Watery Stools, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 | 0 |
| Loose/Watery Stools, Cycle 3 Day 8, Frequency, 3=Frequently | 2 | 1 |
| Loose/Watery Stools, Cycle 3 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Loose/Watery Stools, Cycle 3 Day 15, Frequency, 0=Never | 1 | 5 |
| Loose/Watery Stools, Cycle 3 Day 15, Frequency, 1=Rarely | 2 | 2 |
| Loose/Watery Stools, Cycle 3 Day 15, Frequency, 2=Occasionally | 2 | 0 |
| Loose/Watery Stools, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Loose/Watery Stools, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 1 |
| Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Loose/Watery Stools, End Of Treatment, Frequency, 0=Never | — | 3 |
| Loose/Watery Stools, End Of Treatment, Frequency, 1=Rarely | — | 1 |
| Loose/Watery Stools, End Of Treatment, Frequency, 2=Occasionally | — | 1 |
| Loose/Watery Stools, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Loose/Watery Stools, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Pain in the Abdomen, Baseline, Severity, 0=None | 0 | 1 |
| Pain in the Abdomen, Baseline, Severity, 1=Mild | 6 | 5 |
| Pain in the Abdomen, Baseline, Severity, 2=Moderate | 6 | 4 |
| Pain in the Abdomen, Baseline, Severity, 3=Severe | 0 | 1 |
| Pain in the Abdomen, Baseline, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Baseline, Frequency, 0=Never | 2 | 6 |
| Pain in the Abdomen, Baseline, Frequency, 1=Rarely | 6 | 5 |
| Pain in the Abdomen, Baseline, Frequency, 2=Occasionally | 3 | 4 |
| Pain in the Abdomen, Baseline, Frequency, 3=Frequently | 2 | 2 |
| Pain in the Abdomen, Baseline, Frequency, 4=Almost constantly | 1 | 0 |
| Pain in the Abdomen, Cycle 1 Day 8, Severity, 0=None | 0 | 0 |
| Pain in the Abdomen, Cycle 1 Day 8, Severity, 1=Mild | 4 | 2 |
| Pain in the Abdomen, Cycle 1 Day 8, Severity, 2=Moderate | 4 | 5 |
| Pain in the Abdomen, Cycle 1 Day 8, Severity, 3=Severe | 1 | 2 |
| Pain in the Abdomen, Cycle 1 Day 8, Severity, 4=Very severe | 1 | 0 |
| Pain in the Abdomen, Cycle 1 Day 8, Frequency, 0=Never | 1 | 6 |
| Pain in the Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely | 3 | 1 |
| Pain in the Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally | 3 | 5 |
| Pain in the Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently | 3 | 2 |
| Pain in the Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly | 1 | 1 |
| Pain in the Abdomen, Cycle 1 Day 15, Severity, 0=None | 0 | 0 |
| Pain in the Abdomen, Cycle 1 Day 15, Severity, 1=Mild | 8 | 4 |
| Pain in the Abdomen, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 4 |
| Pain in the Abdomen, Cycle 1 Day 15, Severity, 3=Severe | 1 | 1 |
| Pain in the Abdomen, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 1 Day 15, Frequency, 0=Never | 3 | 4 |
| Pain in the Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely | 6 | 2 |
| Pain in the Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally | 4 | 5 |
| Pain in the Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently | 1 | 1 |
| Pain in the Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 | 1 |
| Pain in the Abdomen, Cycle 2 Day 1, Severity, 0=None | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 1, Severity, 1=Mild | 4 | 1 |
| Pain in the Abdomen, Cycle 2 Day 1, Severity, 2=Moderate | 3 | 3 |
| Pain in the Abdomen, Cycle 2 Day 1, Severity, 3=Severe | 0 | 1 |
| Pain in the Abdomen, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 1, Frequency, 0=Never | 4 | 9 |
| Pain in the Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely | 4 | 1 |
| Pain in the Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally | 3 | 4 |
| Pain in the Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 8, Severity, 0=None | 1 | 0 |
| Pain in the Abdomen, Cycle 2 Day 8, Severity, 1=Mild | 2 | 2 |
| Pain in the Abdomen, Cycle 2 Day 8, Severity, 2=Moderate | 3 | 3 |
| Pain in the Abdomen, Cycle 2 Day 8, Severity, 3=Severe | 1 | 0 |
| Pain in the Abdomen, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 8, Frequency, 0=Never | 4 | 6 |
| Pain in the Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely | 1 | 2 |
| Pain in the Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally | 4 | 3 |
| Pain in the Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently | 1 | 0 |
| Pain in the Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Pain in the Abdomen, Cycle 2 Day 15, Severity, 0=None | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 15, Severity, 1=Mild | 7 | 5 |
| Pain in the Abdomen, Cycle 2 Day 15, Severity, 2=Moderate | 0 | 3 |
| Pain in the Abdomen, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Pain in the Abdomen, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 2 Day 15, Frequency, 0=Never | 6 | 5 |
| Pain in the Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely | 1 | 5 |
| Pain in the Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally | 6 | 3 |
| Pain in the Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently | 0 | 1 |
| Pain in the Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 1, Severity, 0=None | 1 | 0 |
| Pain in the Abdomen, Cycle 3 Day 1, Severity, 1=Mild | 4 | 6 |
| Pain in the Abdomen, Cycle 3 Day 1, Severity, 2=Moderate | 2 | 1 |
| Pain in the Abdomen, Cycle 3 Day 1, Severity, 3=Severe | 1 | 1 |
| Pain in the Abdomen, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 1, Frequency, 0=Never | 6 | 6 |
| Pain in the Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely | 3 | 3 |
| Pain in the Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally | 3 | 4 |
| Pain in the Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently | 1 | 1 |
| Pain in the Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 | 0 |
| Pain in the Abdomen, Cycle 3 Day 8, Severity, 0=None | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 8, Severity, 1=Mild | 4 | 3 |
| Pain in the Abdomen, Cycle 3 Day 8, Severity, 2=Moderate | 2 | 3 |
| Pain in the Abdomen, Cycle 3 Day 8, Severity, 3=Severe | 2 | 1 |
| Pain in the Abdomen, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 8, Frequency, 0=Never | 2 | 3 |
| Pain in the Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely | 3 | 3 |
| Pain in the Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 | 2 |
| Pain in the Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently | 3 | 2 |
| Pain in the Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 15, Severity, 0=None | 2 | 0 |
| Pain in the Abdomen, Cycle 3 Day 15, Severity, 1=Mild | 2 | 3 |
| Pain in the Abdomen, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 1 |
| Pain in the Abdomen, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Pain in the Abdomen, Cycle 3 Day 15, Frequency, 0=Never | 0 | 3 |
| Pain in the Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely | 2 | 1 |
| Pain in the Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally | 3 | 2 |
| Pain in the Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 1 |
| Pain in the Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 1 |
| Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Pain in the Abdomen, End Of Treatment, Severity, 0=None | — | 0 |
| Pain in the Abdomen, End Of Treatment, Severity, 1=Mild | — | 1 |
| Pain in the Abdomen, End Of Treatment, Severity, 2=Moderate | — | 1 |
| Pain in the Abdomen, End Of Treatment, Severity, 3=Severe | — | 0 |
| Pain in the Abdomen, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Pain in the Abdomen, End Of Treatment, Frequency, 0=Never | — | 3 |
| Pain in the Abdomen, End Of Treatment, Frequency, 1=Rarely | — | 1 |
| Pain in the Abdomen, End Of Treatment, Frequency, 2=Occasionally | — | 1 |
| Pain in the Abdomen, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Pain in the Abdomen, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Numb/Tingling Hands/Feet, Baseline, Severity, 0=None | 7 | 15 |
| Numb/Tingling Hands/Feet, Baseline, Severity, 1=Mild | 4 | 2 |
| Numb/Tingling Hands/Feet, Baseline, Severity, 2=Moderate | 2 | 0 |
| Numb/Tingling Hands/Feet, Baseline, Severity, 3=Severe | 1 | 0 |
| Numb/Tingling Hands/Feet, Baseline, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 0=None | 5 | 11 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 1=Mild | 2 | 4 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 2=Moderate | 2 | 0 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 3=Severe | 2 | 0 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 0=None | 5 | 11 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 1=Mild | 6 | 2 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 2=Moderate | 3 | 0 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 3=Severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 0=None | 6 | 14 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 1=Mild | 2 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 2=Moderate | 3 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 0=None | 2 | 10 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 1=Mild | 5 | 1 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 2=Moderate | 2 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 3=Severe | 2 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 0=None | 1 | 13 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 1=Mild | 5 | 1 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 2=Moderate | 5 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 3=Severe | 2 | 0 |
| Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 0=None | 3 | 13 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 1=Mild | 8 | 1 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 2=Moderate | 3 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 3=Severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 0=None | 1 | 8 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 1=Mild | 2 | 2 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 2=Moderate | 5 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 3=Severe | 1 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 4=Very severe | 1 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 0=None | 0 | 5 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 1=Mild | 3 | 2 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 3=Severe | 1 | 0 |
| Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 0=None | 1 | 1 |
| Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 1=Mild | 1 | 0 |
| Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | 0 |
| Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 3=Severe | 0 | 0 |
| Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | 0 |
| Numb/Tingling Hands/Feet, End Of Treatment, Severity, 0=None | — | 4 |
| Numb/Tingling Hands/Feet, End Of Treatment, Severity, 1=Mild | — | 0 |
| Numb/Tingling Hands/Feet, End Of Treatment, Severity, 2=Moderate | — | 1 |
| Numb/Tingling Hands/Feet, End Of Treatment, Severity, 3=Severe | — | 0 |
| Numb/Tingling Hands/Feet, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Probs w/Concentration, Baseline, Severity, 0=None | 4 | 7 |
| Probs w/Concentration, Baseline, Severity, 1=Mild | 8 | 7 |
| Probs w/Concentration, Baseline, Severity, 2=Moderate | 1 | 3 |
| Probs w/Concentration, Baseline, Severity, 3=Severe | 1 | 0 |
| Probs w/Concentration, Baseline, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 1 Day 8, Severity, 0=None | 3 | 4 |
| Probs w/Concentration, Cycle 1 Day 8, Severity, 1=Mild | 2 | 10 |
| Probs w/Concentration, Cycle 1 Day 8, Severity, 2=Moderate | 6 | 1 |
| Probs w/Concentration, Cycle 1 Day 8, Severity, 3=Severe | 0 | 0 |
| Probs w/Concentration, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 1 Day 15, Severity, 0=None | 7 | 7 |
| Probs w/Concentration, Cycle 1 Day 15, Severity, 1=Mild | 5 | 3 |
| Probs w/Concentration, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 3 |
| Probs w/Concentration, Cycle 1 Day 15, Severity, 3=Severe | 0 | 0 |
| Probs w/Concentration, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 2 Day 1, Severity, 0=None | 5 | 6 |
| Probs w/Concentration, Cycle 2 Day 1, Severity, 1=Mild | 4 | 6 |
| Probs w/Concentration, Cycle 2 Day 1, Severity, 2=Moderate | 2 | 2 |
| Probs w/Concentration, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Probs w/Concentration, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 2 Day 8, Severity, 0=None | 3 | 7 |
| Probs w/Concentration, Cycle 2 Day 8, Severity, 1=Mild | 4 | 4 |
| Probs w/Concentration, Cycle 2 Day 8, Severity, 2=Moderate | 3 | 0 |
| Probs w/Concentration, Cycle 2 Day 8, Severity, 3=Severe | 0 | 0 |
| Probs w/Concentration, Cycle 2 Day 8, Severity, 4=Very severe | 1 | 0 |
| Probs w/Concentration, Cycle 2 Day 15, Severity, 0=None | 4 | 9 |
| Probs w/Concentration, Cycle 2 Day 15, Severity, 1=Mild | 8 | 4 |
| Probs w/Concentration, Cycle 2 Day 15, Severity, 2=Moderate | 1 | 1 |
| Probs w/Concentration, Cycle 2 Day 15, Severity, 3=Severe | 0 | 0 |
| Probs w/Concentration, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 3 Day 1, Severity, 0=None | 8 | 9 |
| Probs w/Concentration, Cycle 3 Day 1, Severity, 1=Mild | 5 | 3 |
| Probs w/Concentration, Cycle 3 Day 1, Severity, 2=Moderate | 1 | 1 |
| Probs w/Concentration, Cycle 3 Day 1, Severity, 3=Severe | 0 | 1 |
| Probs w/Concentration, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 3 Day 8, Severity, 0=None | 4 | 5 |
| Probs w/Concentration, Cycle 3 Day 8, Severity, 1=Mild | 1 | 4 |
| Probs w/Concentration, Cycle 3 Day 8, Severity, 2=Moderate | 4 | 1 |
| Probs w/Concentration, Cycle 3 Day 8, Severity, 3=Severe | 1 | 0 |
| Probs w/Concentration, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Cycle 3 Day 15, Severity, 0=None | 1 | 4 |
| Probs w/Concentration, Cycle 3 Day 15, Severity, 1=Mild | 3 | 2 |
| Probs w/Concentration, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 1 |
| Probs w/Concentration, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Probs w/Concentration, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, Pre-IDS Evaluation, Severity, 0=None | 2 | 0 |
| Probs w/Concentration, Pre-IDS Evaluation, Severity, 1=Mild | 0 | 0 |
| Probs w/Concentration, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | 0 |
| Probs w/Concentration, Pre-IDS Evaluation, Severity, 3=Severe | 0 | 1 |
| Probs w/Concentration, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | 0 |
| Probs w/Concentration, End Of Treatment, Severity, 0=None | — | 3 |
| Probs w/Concentration, End Of Treatment, Severity, 1=Mild | — | 1 |
| Probs w/Concentration, End Of Treatment, Severity, 2=Moderate | — | 1 |
| Probs w/Concentration, End Of Treatment, Severity, 3=Severe | — | 0 |
| Probs w/Concentration, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Problems w/Memory, Baseline, Severity, 0=None | 7 | 6 |
| Problems w/Memory, Baseline, Severity, 1=Mild | 6 | 8 |
| Problems w/Memory, Baseline, Severity, 2=Moderate | 0 | 2 |
| Problems w/Memory, Baseline, Severity, 3=Severe | 0 | 1 |
| Problems w/Memory, Baseline, Severity, 4=Very severe | 1 | 0 |
| Problems w/Memory, Cycle 1 Day 8, Severity, 0=None | 7 | 5 |
| Problems w/Memory, Cycle 1 Day 8, Severity, 1=Mild | 3 | 8 |
| Problems w/Memory, Cycle 1 Day 8, Severity, 2=Moderate | 1 | 2 |
| Problems w/Memory, Cycle 1 Day 8, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Cycle 1 Day 15, Severity, 0=None | 6 | 5 |
| Problems w/Memory, Cycle 1 Day 15, Severity, 1=Mild | 7 | 6 |
| Problems w/Memory, Cycle 1 Day 15, Severity, 2=Moderate | 1 | 2 |
| Problems w/Memory, Cycle 1 Day 15, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Cycle 2 Day 1, Severity, 0=None | 5 | 6 |
| Problems w/Memory, Cycle 2 Day 1, Severity, 1=Mild | 4 | 5 |
| Problems w/Memory, Cycle 2 Day 1, Severity, 2=Moderate | 2 | 3 |
| Problems w/Memory, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Cycle 2 Day 8, Severity, 0=None | 5 | 6 |
| Problems w/Memory, Cycle 2 Day 8, Severity, 1=Mild | 5 | 4 |
| Problems w/Memory, Cycle 2 Day 8, Severity, 2=Moderate | 1 | 1 |
| Problems w/Memory, Cycle 2 Day 8, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Cycle 2 Day 15, Severity, 0=None | 6 | 5 |
| Problems w/Memory, Cycle 2 Day 15, Severity, 1=Mild | 7 | 7 |
| Problems w/Memory, Cycle 2 Day 15, Severity, 2=Moderate | 0 | 1 |
| Problems w/Memory, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Problems w/Memory, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Cycle 3 Day 1, Severity, 0=None | 8 | 9 |
| Problems w/Memory, Cycle 3 Day 1, Severity, 1=Mild | 6 | 3 |
| Problems w/Memory, Cycle 3 Day 1, Severity, 2=Moderate | 0 | 1 |
| Problems w/Memory, Cycle 3 Day 1, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 1 |
| Problems w/Memory, Cycle 3 Day 8, Severity, 0=None | 5 | 4 |
| Problems w/Memory, Cycle 3 Day 8, Severity, 1=Mild | 1 | 5 |
| Problems w/Memory, Cycle 3 Day 8, Severity, 2=Moderate | 3 | 1 |
| Problems w/Memory, Cycle 3 Day 8, Severity, 3=Severe | 1 | 0 |
| Problems w/Memory, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Cycle 3 Day 15, Severity, 0=None | 2 | 4 |
| Problems w/Memory, Cycle 3 Day 15, Severity, 1=Mild | 3 | 2 |
| Problems w/Memory, Cycle 3 Day 15, Severity, 2=Moderate | 0 | 1 |
| Problems w/Memory, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Problems w/Memory, Pre-IDS Evaluation, Severity, 0=None | 2 | 0 |
| Problems w/Memory, Pre-IDS Evaluation, Severity, 1=Mild | 0 | 0 |
| Problems w/Memory, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | 0 |
| Problems w/Memory, Pre-IDS Evaluation, Severity, 3=Severe | 0 | 0 |
| Problems w/Memory, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | 1 |
| Problems w/Memory, End Of Treatment, Severity, 0=None | — | 4 |
| Problems w/Memory, End Of Treatment, Severity, 1=Mild | — | 1 |
| Problems w/Memory, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Problems w/Memory, End Of Treatment, Severity, 3=Severe | — | 0 |
| Problems w/Memory, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Aching Muscles, Baseline, Severity, 0=None | 1 | 0 |
| Aching Muscles, Baseline, Severity, 1=Mild | 0 | 4 |
| Aching Muscles, Baseline, Severity, 2=Moderate | 1 | 4 |
| Aching Muscles, Baseline, Severity, 3=Severe | 1 | 2 |
| Aching Muscles, Baseline, Severity, 4=Very severe | 0 | 0 |
| Aching Muscles, Baseline, Frequency, 0=Never | 11 | 7 |
| Aching Muscles, Baseline, Frequency, 1=Rarely | 1 | 6 |
| Aching Muscles, Baseline, Frequency, 2=Occasionally | 1 | 2 |
| Aching Muscles, Baseline, Frequency, 3=Frequently | 0 | 2 |
| Aching Muscles, Baseline, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Muscles, Cycle 1 Day 8, Severity, 0=None | 1 | 0 |
| Aching Muscles, Cycle 1 Day 8, Severity, 1=Mild | 1 | 4 |
| Aching Muscles, Cycle 1 Day 8, Severity, 2=Moderate | 2 | 3 |
| Aching Muscles, Cycle 1 Day 8, Severity, 3=Severe | 1 | 0 |
| Aching Muscles, Cycle 1 Day 8, Severity, 4=Very severe | 4 | 0 |
| Aching Muscles, Cycle 1 Day 8, Frequency, 0=Never | 2 | 8 |
| Aching Muscles, Cycle 1 Day 8, Frequency, 1=Rarely | 2 | 3 |
| Aching Muscles, Cycle 1 Day 8, Frequency, 2=Occasionally | 2 | 2 |
| Aching Muscles, Cycle 1 Day 8, Frequency, 3=Frequently | 1 | 2 |
| Aching Muscles, Cycle 1 Day 8, Frequency, 4=Almost constantly | 4 | 0 |
| Aching Muscles, Cycle 1 Day 15, Severity, 0=None | 1 | 0 |
| Aching Muscles, Cycle 1 Day 15, Severity, 1=Mild | 5 | 1 |
| Aching Muscles, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 3 |
| Aching Muscles, Cycle 1 Day 15, Severity, 3=Severe | 0 | 1 |
| Aching Muscles, Cycle 1 Day 15, Severity, 4=Very severe | 1 | 0 |
| Aching Muscles, Cycle 1 Day 15, Frequency, 0=Never | 5 | 8 |
| Aching Muscles, Cycle 1 Day 15, Frequency, 1=Rarely | 3 | 1 |
| Aching Muscles, Cycle 1 Day 15, Frequency, 2=Occasionally | 5 | 4 |
| Aching Muscles, Cycle 1 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Aching Muscles, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Muscles, Cycle 2 Day 1, Severity, 0=None | 0 | 0 |
| Aching Muscles, Cycle 2 Day 1, Severity, 1=Mild | 3 | 2 |
| Aching Muscles, Cycle 2 Day 1, Severity, 2=Moderate | 0 | 4 |
| Aching Muscles, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Aching Muscles, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Aching Muscles, Cycle 2 Day 1, Frequency, 0=Never | 8 | 8 |
| Aching Muscles, Cycle 2 Day 1, Frequency, 1=Rarely | 1 | 1 |
| Aching Muscles, Cycle 2 Day 1, Frequency, 2=Occasionally | 2 | 3 |
| Aching Muscles, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 2 |
| Aching Muscles, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Aching Muscles, Cycle 2 Day 8, Severity, 0=None | 0 | 0 |
| Aching Muscles, Cycle 2 Day 8, Severity, 1=Mild | 3 | 2 |
| Aching Muscles, Cycle 2 Day 8, Severity, 2=Moderate | 4 | 2 |
| Aching Muscles, Cycle 2 Day 8, Severity, 3=Severe | 2 | 1 |
| Aching Muscles, Cycle 2 Day 8, Severity, 4=Very severe | 1 | 0 |
| Aching Muscles, Cycle 2 Day 8, Frequency, 0=Never | 1 | 6 |
| Aching Muscles, Cycle 2 Day 8, Frequency, 1=Rarely | 4 | 2 |
| Aching Muscles, Cycle 2 Day 8, Frequency, 2=Occasionally | 1 | 2 |
| Aching Muscles, Cycle 2 Day 8, Frequency, 3=Frequently | 4 | 1 |
| Aching Muscles, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Muscles, Cycle 2 Day 15, Severity, 0=None | 0 | 0 |
| Aching Muscles, Cycle 2 Day 15, Severity, 1=Mild | 5 | 6 |
| Aching Muscles, Cycle 2 Day 15, Severity, 2=Moderate | 1 | 0 |
| Aching Muscles, Cycle 2 Day 15, Severity, 3=Severe | 2 | 1 |
| Aching Muscles, Cycle 2 Day 15, Severity, 4=Very severe | 1 | 0 |
| Aching Muscles, Cycle 2 Day 15, Frequency, 0=Never | 4 | 7 |
| Aching Muscles, Cycle 2 Day 15, Frequency, 1=Rarely | 3 | 5 |
| Aching Muscles, Cycle 2 Day 15, Frequency, 2=Occasionally | 4 | 1 |
| Aching Muscles, Cycle 2 Day 15, Frequency, 3=Frequently | 1 | 1 |
| Aching Muscles, Cycle 2 Day 15, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Muscles, Cycle 3 Day 1, Severity, 0=None | 1 | 0 |
| Aching Muscles, Cycle 3 Day 1, Severity, 1=Mild | 5 | 6 |
| Aching Muscles, Cycle 3 Day 1, Severity, 2=Moderate | 1 | 1 |
| Aching Muscles, Cycle 3 Day 1, Severity, 3=Severe | 1 | 1 |
| Aching Muscles, Cycle 3 Day 1, Severity, 4=Very severe | 1 | 0 |
| Aching Muscles, Cycle 3 Day 1, Frequency, 0=Never | 5 | 6 |
| Aching Muscles, Cycle 3 Day 1, Frequency, 1=Rarely | 5 | 5 |
| Aching Muscles, Cycle 3 Day 1, Frequency, 2=Occasionally | 2 | 1 |
| Aching Muscles, Cycle 3 Day 1, Frequency, 3=Frequently | 1 | 1 |
| Aching Muscles, Cycle 3 Day 1, Frequency, 4=Almost constantly | 1 | 1 |
| Aching Muscles, Cycle 3 Day 8, Severity, 0=None | 0 | 0 |
| Aching Muscles, Cycle 3 Day 8, Severity, 1=Mild | 1 | 2 |
| Aching Muscles, Cycle 3 Day 8, Severity, 2=Moderate | 2 | 2 |
| Aching Muscles, Cycle 3 Day 8, Severity, 3=Severe | 3 | 1 |
| Aching Muscles, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Aching Muscles, Cycle 3 Day 8, Frequency, 0=Never | 4 | 5 |
| Aching Muscles, Cycle 3 Day 8, Frequency, 1=Rarely | 1 | 2 |
| Aching Muscles, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 | 2 |
| Aching Muscles, Cycle 3 Day 8, Frequency, 3=Frequently | 3 | 1 |
| Aching Muscles, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Aching Muscles, Cycle 3 Day 15, Severity, 0=None | 1 | 0 |
| Aching Muscles, Cycle 3 Day 15, Severity, 1=Mild | 1 | 3 |
| Aching Muscles, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 0 |
| Aching Muscles, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Aching Muscles, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Aching Muscles, Cycle 3 Day 15, Frequency, 0=Never | 2 | 4 |
| Aching Muscles, Cycle 3 Day 15, Frequency, 1=Rarely | 1 | 2 |
| Aching Muscles, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 | 1 |
| Aching Muscles, Cycle 3 Day 15, Frequency, 3=Frequently | 1 | 0 |
| Aching Muscles, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Aching Muscles, Pre-IDS Evaluation, Severity, 0=None | 0 | — |
| Aching Muscles, Pre-IDS Evaluation, Severity, 1=Mild | 1 | — |
| Aching Muscles, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | — |
| Aching Muscles, Pre-IDS Evaluation, Severity, 3=Severe | 0 | — |
| Aching Muscles, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | — |
| Aching Muscles, Pre-IDS Evaluation, Frequency, 0=Never | 1 | 1 |
| Aching Muscles, Pre-IDS Evaluation, Frequency, 1=Rarely | 1 | 0 |
| Aching Muscles, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Aching Muscles, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Aching Muscles, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Aching Muscles, End Of Treatment, Severity, 0=None | — | 0 |
| Aching Muscles, End Of Treatment, Severity, 1=Mild | — | 4 |
| Aching Muscles, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Aching Muscles, End Of Treatment, Severity, 3=Severe | — | 0 |
| Aching Muscles, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Aching Muscles, End Of Treatment, Frequency, 0=Never | — | 1 |
| Aching Muscles, End Of Treatment, Frequency, 1=Rarely | — | 4 |
| Aching Muscles, End Of Treatment, Frequency, 2=Occasionally | — | 0 |
| Aching Muscles, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Aching Muscles, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Aching Joints, Baseline, Severity, 0=None | 0 | 0 |
| Aching Joints, Baseline, Severity, 1=Mild | 3 | 3 |
| Aching Joints, Baseline, Severity, 2=Moderate | 1 | 1 |
| Aching Joints, Baseline, Severity, 3=Severe | 1 | 2 |
| Aching Joints, Baseline, Severity, 4=Very severe | 0 | 0 |
| Aching Joints, Baseline, Frequency, 0=Never | 9 | 11 |
| Aching Joints, Baseline, Frequency, 1=Rarely | 3 | 3 |
| Aching Joints, Baseline, Frequency, 2=Occasionally | 1 | 1 |
| Aching Joints, Baseline, Frequency, 3=Frequently | 1 | 1 |
| Aching Joints, Baseline, Frequency, 4=Almost constantly | 0 | 1 |
| Aching Joints, Cycle 1 Day 8, Severity, 0=None | 0 | 0 |
| Aching Joints, Cycle 1 Day 8, Severity, 1=Mild | 3 | 1 |
| Aching Joints, Cycle 1 Day 8, Severity, 2=Moderate | 1 | 1 |
| Aching Joints, Cycle 1 Day 8, Severity, 3=Severe | 3 | 1 |
| Aching Joints, Cycle 1 Day 8, Severity, 4=Very severe | 1 | 0 |
| Aching Joints, Cycle 1 Day 8, Frequency, 0=Never | 3 | 12 |
| Aching Joints, Cycle 1 Day 8, Frequency, 1=Rarely | 4 | 0 |
| Aching Joints, Cycle 1 Day 8, Frequency, 2=Occasionally | 0 | 2 |
| Aching Joints, Cycle 1 Day 8, Frequency, 3=Frequently | 2 | 0 |
| Aching Joints, Cycle 1 Day 8, Frequency, 4=Almost constantly | 2 | 1 |
| Aching Joints, Cycle 1 Day 15, Severity, 0=None | 0 | 0 |
| Aching Joints, Cycle 1 Day 15, Severity, 1=Mild | 4 | 3 |
| Aching Joints, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 2 |
| Aching Joints, Cycle 1 Day 15, Severity, 3=Severe | 0 | 0 |
| Aching Joints, Cycle 1 Day 15, Severity, 4=Very severe | 1 | 0 |
| Aching Joints, Cycle 1 Day 15, Frequency, 0=Never | 7 | 8 |
| Aching Joints, Cycle 1 Day 15, Frequency, 1=Rarely | 4 | 3 |
| Aching Joints, Cycle 1 Day 15, Frequency, 2=Occasionally | 2 | 2 |
| Aching Joints, Cycle 1 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Aching Joints, Cycle 1 Day 15, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Joints, Cycle 2 Day 1, Severity, 0=None | 1 | 1 |
| Aching Joints, Cycle 2 Day 1, Severity, 1=Mild | 4 | 1 |
| Aching Joints, Cycle 2 Day 1, Severity, 2=Moderate | 1 | 3 |
| Aching Joints, Cycle 2 Day 1, Severity, 3=Severe | 0 | 1 |
| Aching Joints, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Aching Joints, Cycle 2 Day 1, Frequency, 0=Never | 5 | 8 |
| Aching Joints, Cycle 2 Day 1, Frequency, 1=Rarely | 4 | 2 |
| Aching Joints, Cycle 2 Day 1, Frequency, 2=Occasionally | 1 | 3 |
| Aching Joints, Cycle 2 Day 1, Frequency, 3=Frequently | 1 | 1 |
| Aching Joints, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Aching Joints, Cycle 2 Day 8, Severity, 0=None | 1 | 0 |
| Aching Joints, Cycle 2 Day 8, Severity, 1=Mild | 2 | 3 |
| Aching Joints, Cycle 2 Day 8, Severity, 2=Moderate | 4 | 0 |
| Aching Joints, Cycle 2 Day 8, Severity, 3=Severe | 2 | 1 |
| Aching Joints, Cycle 2 Day 8, Severity, 4=Very severe | 1 | 0 |
| Aching Joints, Cycle 2 Day 8, Frequency, 0=Never | 1 | 7 |
| Aching Joints, Cycle 2 Day 8, Frequency, 1=Rarely | 3 | 2 |
| Aching Joints, Cycle 2 Day 8, Frequency, 2=Occasionally | 4 | 1 |
| Aching Joints, Cycle 2 Day 8, Frequency, 3=Frequently | 2 | 1 |
| Aching Joints, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Joints, Cycle 2 Day 15, Severity, 0=None | 2 | 0 |
| Aching Joints, Cycle 2 Day 15, Severity, 1=Mild | 5 | 3 |
| Aching Joints, Cycle 2 Day 15, Severity, 2=Moderate | 2 | 1 |
| Aching Joints, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Aching Joints, Cycle 2 Day 15, Severity, 4=Very severe | 1 | 0 |
| Aching Joints, Cycle 2 Day 15, Frequency, 0=Never | 3 | 9 |
| Aching Joints, Cycle 2 Day 15, Frequency, 1=Rarely | 5 | 3 |
| Aching Joints, Cycle 2 Day 15, Frequency, 2=Occasionally | 3 | 1 |
| Aching Joints, Cycle 2 Day 15, Frequency, 3=Frequently | 1 | 1 |
| Aching Joints, Cycle 2 Day 15, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Joints, Cycle 3 Day 1, Severity, 0=None | 0 | 1 |
| Aching Joints, Cycle 3 Day 1, Severity, 1=Mild | 3 | 3 |
| Aching Joints, Cycle 3 Day 1, Severity, 2=Moderate | 4 | 1 |
| Aching Joints, Cycle 3 Day 1, Severity, 3=Severe | 1 | 1 |
| Aching Joints, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Aching Joints, Cycle 3 Day 1, Frequency, 0=Never | 6 | 8 |
| Aching Joints, Cycle 3 Day 1, Frequency, 1=Rarely | 3 | 4 |
| Aching Joints, Cycle 3 Day 1, Frequency, 2=Occasionally | 3 | 0 |
| Aching Joints, Cycle 3 Day 1, Frequency, 3=Frequently | 2 | 1 |
| Aching Joints, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 | 1 |
| Aching Joints, Cycle 3 Day 8, Severity, 0=None | 1 | 0 |
| Aching Joints, Cycle 3 Day 8, Severity, 1=Mild | 0 | 4 |
| Aching Joints, Cycle 3 Day 8, Severity, 2=Moderate | 2 | 0 |
| Aching Joints, Cycle 3 Day 8, Severity, 3=Severe | 3 | 1 |
| Aching Joints, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Aching Joints, Cycle 3 Day 8, Frequency, 0=Never | 4 | 5 |
| Aching Joints, Cycle 3 Day 8, Frequency, 1=Rarely | 1 | 3 |
| Aching Joints, Cycle 3 Day 8, Frequency, 2=Occasionally | 0 | 1 |
| Aching Joints, Cycle 3 Day 8, Frequency, 3=Frequently | 4 | 1 |
| Aching Joints, Cycle 3 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Joints, Cycle 3 Day 15, Severity, 0=None | 1 | 0 |
| Aching Joints, Cycle 3 Day 15, Severity, 1=Mild | 1 | 2 |
| Aching Joints, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 0 |
| Aching Joints, Cycle 3 Day 15, Severity, 3=Severe | 1 | 0 |
| Aching Joints, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Aching Joints, Cycle 3 Day 15, Frequency, 0=Never | 1 | 5 |
| Aching Joints, Cycle 3 Day 15, Frequency, 1=Rarely | 2 | 1 |
| Aching Joints, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 | 1 |
| Aching Joints, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Aching Joints, Cycle 3 Day 15, Frequency, 4=Almost constantly | 1 | 0 |
| Aching Joints, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 1 |
| Aching Joints, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Aching Joints, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Aching Joints, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Aching Joints, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Aching Joints, End Of Treatment, Severity, 0=None | — | 1 |
| Aching Joints, End Of Treatment, Severity, 1=Mild | — | 1 |
| Aching Joints, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Aching Joints, End Of Treatment, Severity, 3=Severe | — | 0 |
| Aching Joints, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Aching Joints, End Of Treatment, Frequency, 0=Never | — | 3 |
| Aching Joints, End Of Treatment, Frequency, 1=Rarely | — | 2 |
| Aching Joints, End Of Treatment, Frequency, 2=Occasionally | — | 0 |
| Aching Joints, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Aching Joints, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Fatigue/Lack of Energy, Baseline, Severity, 0=None | 3 | 3 |
| Fatigue/Lack of Energy, Baseline, Severity, 1=Mild | 2 | 5 |
| Fatigue/Lack of Energy, Baseline, Severity, 2=Moderate | 8 | 6 |
| Fatigue/Lack of Energy, Baseline, Severity, 3=Severe | 1 | 3 |
| Fatigue/Lack of Energy, Baseline, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 0=None | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 1=Mild | 1 | 7 |
| Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 2=Moderate | 3 | 2 |
| Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 3=Severe | 7 | 6 |
| Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 0=None | 2 | 2 |
| Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 1=Mild | 5 | 3 |
| Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 2=Moderate | 5 | 4 |
| Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 3=Severe | 1 | 4 |
| Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 4=Very severe | 1 | 0 |
| Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 0=None | 3 | 1 |
| Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 1=Mild | 4 | 6 |
| Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 2=Moderate | 4 | 5 |
| Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 3=Severe | 0 | 2 |
| Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 0=None | 0 | 1 |
| Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 1=Mild | 4 | 6 |
| Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 2=Moderate | 3 | 3 |
| Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 3=Severe | 2 | 1 |
| Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 4=Very severe | 2 | 0 |
| Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 0=None | 2 | 2 |
| Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 1=Mild | 2 | 5 |
| Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 2=Moderate | 7 | 6 |
| Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 3=Severe | 2 | 1 |
| Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 0=None | 2 | 2 |
| Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 1=Mild | 7 | 6 |
| Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 2=Moderate | 5 | 4 |
| Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 3=Severe | 0 | 2 |
| Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 0=None | 0 | 1 |
| Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 1=Mild | 2 | 3 |
| Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 2=Moderate | 3 | 5 |
| Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 3=Severe | 3 | 1 |
| Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 4=Very severe | 2 | 0 |
| Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 0=None | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 1=Mild | 4 | 3 |
| Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 2=Moderate | 1 | 4 |
| Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 0=None | 1 | 0 |
| Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 1=Mild | 1 | 0 |
| Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 2=Moderate | 0 | 1 |
| Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 3=Severe | 0 | 0 |
| Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 4=Very severe | 0 | 0 |
| Fatigue/Lack of Energy, End Of Treatment, Severity, 0=None | — | 2 |
| Fatigue/Lack of Energy, End Of Treatment, Severity, 1=Mild | — | 2 |
| Fatigue/Lack of Energy, End Of Treatment, Severity, 2=Moderate | — | 1 |
| Fatigue/Lack of Energy, End Of Treatment, Severity, 3=Severe | — | 0 |
| Fatigue/Lack of Energy, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Anxiety, Baseline, Severity, 0=None | 1 | 1 |
| Anxiety, Baseline, Severity, 1=Mild | 5 | 6 |
| Anxiety, Baseline, Severity, 2=Moderate | 4 | 3 |
| Anxiety, Baseline, Severity, 3=Severe | 0 | 1 |
| Anxiety, Baseline, Severity, 4=Very severe | 0 | 1 |
| Anxiety, Baseline, Frequency, 0=Never | 4 | 5 |
| Anxiety, Baseline, Frequency, 1=Rarely | 4 | 6 |
| Anxiety, Baseline, Frequency, 2=Occasionally | 5 | 4 |
| Anxiety, Baseline, Frequency, 3=Frequently | 0 | 0 |
| Anxiety, Baseline, Frequency, 4=Almost constantly | 1 | 2 |
| Anxiety, Cycle 1 Day 8, Severity, 0=None | 2 | 0 |
| Anxiety, Cycle 1 Day 8, Severity, 1=Mild | 4 | 3 |
| Anxiety, Cycle 1 Day 8, Severity, 2=Moderate | 1 | 3 |
| Anxiety, Cycle 1 Day 8, Severity, 3=Severe | 1 | 2 |
| Anxiety, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 1 Day 8, Frequency, 0=Never | 3 | 7 |
| Anxiety, Cycle 1 Day 8, Frequency, 1=Rarely | 6 | 3 |
| Anxiety, Cycle 1 Day 8, Frequency, 2=Occasionally | 1 | 2 |
| Anxiety, Cycle 1 Day 8, Frequency, 3=Frequently | 1 | 2 |
| Anxiety, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 | 1 |
| Anxiety, Cycle 1 Day 15, Severity, 0=None | 1 | 0 |
| Anxiety, Cycle 1 Day 15, Severity, 1=Mild | 4 | 3 |
| Anxiety, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 2 |
| Anxiety, Cycle 1 Day 15, Severity, 3=Severe | 0 | 2 |
| Anxiety, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 1 Day 15, Frequency, 0=Never | 7 | 6 |
| Anxiety, Cycle 1 Day 15, Frequency, 1=Rarely | 6 | 3 |
| Anxiety, Cycle 1 Day 15, Frequency, 2=Occasionally | 0 | 3 |
| Anxiety, Cycle 1 Day 15, Frequency, 3=Frequently | 1 | 1 |
| Anxiety, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, Cycle 2 Day 1, Severity, 0=None | 0 | 1 |
| Anxiety, Cycle 2 Day 1, Severity, 1=Mild | 4 | 6 |
| Anxiety, Cycle 2 Day 1, Severity, 2=Moderate | 2 | 0 |
| Anxiety, Cycle 2 Day 1, Severity, 3=Severe | 0 | 1 |
| Anxiety, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 2 Day 1, Frequency, 0=Never | 5 | 6 |
| Anxiety, Cycle 2 Day 1, Frequency, 1=Rarely | 4 | 6 |
| Anxiety, Cycle 2 Day 1, Frequency, 2=Occasionally | 2 | 2 |
| Anxiety, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 0 |
| Anxiety, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, Cycle 2 Day 8, Severity, 0=None | 1 | 0 |
| Anxiety, Cycle 2 Day 8, Severity, 1=Mild | 2 | 3 |
| Anxiety, Cycle 2 Day 8, Severity, 2=Moderate | 3 | 1 |
| Anxiety, Cycle 2 Day 8, Severity, 3=Severe | 1 | 0 |
| Anxiety, Cycle 2 Day 8, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 2 Day 8, Frequency, 0=Never | 4 | 7 |
| Anxiety, Cycle 2 Day 8, Frequency, 1=Rarely | 2 | 3 |
| Anxiety, Cycle 2 Day 8, Frequency, 2=Occasionally | 4 | 1 |
| Anxiety, Cycle 2 Day 8, Frequency, 3=Frequently | 1 | 0 |
| Anxiety, Cycle 2 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, Cycle 2 Day 15, Severity, 0=None | 0 | 0 |
| Anxiety, Cycle 2 Day 15, Severity, 1=Mild | 4 | 3 |
| Anxiety, Cycle 2 Day 15, Severity, 2=Moderate | 4 | 2 |
| Anxiety, Cycle 2 Day 15, Severity, 3=Severe | 0 | 1 |
| Anxiety, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 2 Day 15, Frequency, 0=Never | 5 | 8 |
| Anxiety, Cycle 2 Day 15, Frequency, 1=Rarely | 2 | 2 |
| Anxiety, Cycle 2 Day 15, Frequency, 2=Occasionally | 6 | 1 |
| Anxiety, Cycle 2 Day 15, Frequency, 3=Frequently | 0 | 2 |
| Anxiety, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 1 |
| Anxiety, Cycle 3 Day 1, Severity, 0=None | 1 | 0 |
| Anxiety, Cycle 3 Day 1, Severity, 1=Mild | 7 | 5 |
| Anxiety, Cycle 3 Day 1, Severity, 2=Moderate | 1 | 3 |
| Anxiety, Cycle 3 Day 1, Severity, 3=Severe | 0 | 0 |
| Anxiety, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 3 Day 1, Frequency, 0=Never | 5 | 6 |
| Anxiety, Cycle 3 Day 1, Frequency, 1=Rarely | 5 | 5 |
| Anxiety, Cycle 3 Day 1, Frequency, 2=Occasionally | 4 | 2 |
| Anxiety, Cycle 3 Day 1, Frequency, 3=Frequently | 0 | 1 |
| Anxiety, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, Cycle 3 Day 8, Severity, 0=None | 1 | 0 |
| Anxiety, Cycle 3 Day 8, Severity, 1=Mild | 1 | 3 |
| Anxiety, Cycle 3 Day 8, Severity, 2=Moderate | 3 | 3 |
| Anxiety, Cycle 3 Day 8, Severity, 3=Severe | 0 | 0 |
| Anxiety, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 3 Day 8, Frequency, 0=Never | 5 | 4 |
| Anxiety, Cycle 3 Day 8, Frequency, 1=Rarely | 1 | 3 |
| Anxiety, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 | 2 |
| Anxiety, Cycle 3 Day 8, Frequency, 3=Frequently | 2 | 1 |
| Anxiety, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, Cycle 3 Day 15, Severity, 0=None | 1 | 0 |
| Anxiety, Cycle 3 Day 15, Severity, 1=Mild | 1 | 4 |
| Anxiety, Cycle 3 Day 15, Severity, 2=Moderate | 2 | 0 |
| Anxiety, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Anxiety, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Anxiety, Cycle 3 Day 15, Frequency, 0=Never | 1 | 3 |
| Anxiety, Cycle 3 Day 15, Frequency, 1=Rarely | 2 | 3 |
| Anxiety, Cycle 3 Day 15, Frequency, 2=Occasionally | 2 | 1 |
| Anxiety, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Anxiety, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, Pre-IDS Evaluation, Severity, 0=None | — | 0 |
| Anxiety, Pre-IDS Evaluation, Severity, 1=Mild | — | 1 |
| Anxiety, Pre-IDS Evaluation, Severity, 2=Moderate | — | 0 |
| Anxiety, Pre-IDS Evaluation, Severity, 3=Severe | — | 0 |
| Anxiety, Pre-IDS Evaluation, Severity, 4=Very severe | — | 0 |
| Anxiety, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 0 |
| Anxiety, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 1 |
| Anxiety, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 0 |
| Anxiety, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Anxiety, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Anxiety, End Of Treatment, Severity, 0=None | — | 1 |
| Anxiety, End Of Treatment, Severity, 1=Mild | — | 2 |
| Anxiety, End Of Treatment, Severity, 2=Moderate | — | 1 |
| Anxiety, End Of Treatment, Severity, 3=Severe | — | 0 |
| Anxiety, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Anxiety, End Of Treatment, Frequency, 0=Never | — | 1 |
| Anxiety, End Of Treatment, Frequency, 1=Rarely | — | 2 |
| Anxiety, End Of Treatment, Frequency, 2=Occasionally | — | 2 |
| Anxiety, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Anxiety, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
| Sad or Unhappy Feelings, Baseline, Severity, 0=None | 1 | 2 |
| Sad or Unhappy Feelings, Baseline, Severity, 1=Mild | 8 | 5 |
| Sad or Unhappy Feelings, Baseline, Severity, 2=Moderate | 3 | 4 |
| Sad or Unhappy Feelings, Baseline, Severity, 3=Severe | 0 | 1 |
| Sad or Unhappy Feelings, Baseline, Severity, 4=Very severe | 0 | 1 |
| Sad or Unhappy Feelings, Baseline, Frequency, 0=Never | 2 | 4 |
| Sad or Unhappy Feelings, Baseline, Frequency, 1=Rarely | 4 | 6 |
| Sad or Unhappy Feelings, Baseline, Frequency, 2=Occasionally | 8 | 5 |
| Sad or Unhappy Feelings, Baseline, Frequency, 3=Frequently | 0 | 1 |
| Sad or Unhappy Feelings, Baseline, Frequency, 4=Almost constantly | 0 | 1 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 0=None | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 1=Mild | 6 | 5 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 2=Moderate | 2 | 2 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 3=Severe | 1 | 2 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 0=Never | 1 | 5 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 1=Rarely | 5 | 6 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 2=Occasionally | 4 | 3 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 3=Frequently | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 4=Almost constantly | 0 | 1 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 0=None | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 1=Mild | 5 | 5 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 2=Moderate | 2 | 2 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 3=Severe | 0 | 2 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 0=Never | 6 | 4 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 1=Rarely | 5 | 5 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 2=Occasionally | 2 | 3 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 3=Frequently | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 0=None | 0 | 1 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 1=Mild | 3 | 7 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 2=Moderate | 2 | 1 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 3=Severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 0=Never | 6 | 5 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 1=Rarely | 1 | 8 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 2=Occasionally | 4 | 1 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 3=Frequently | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 0=None | 1 | 2 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 1=Mild | 3 | 6 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 2=Moderate | 2 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 3=Severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 4=Very severe | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 0=Never | 4 | 3 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 1=Rarely | 3 | 8 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 2=Occasionally | 2 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 3=Frequently | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 4=Almost constantly | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 0=None | 0 | 3 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 1=Mild | 5 | 6 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 2=Moderate | 4 | 2 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 3=Severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 0=Never | 4 | 3 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 1=Rarely | 4 | 7 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 2=Occasionally | 4 | 3 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 3=Frequently | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 0=None | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 1=Mild | 6 | 8 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 2=Moderate | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 3=Severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 0=Never | 6 | 4 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 1=Rarely | 6 | 9 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 2=Occasionally | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 3=Frequently | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 0=None | 2 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 1=Mild | 0 | 4 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 2=Moderate | 2 | 2 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 3=Severe | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 0=Never | 5 | 3 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 1=Rarely | 2 | 5 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 2=Occasionally | 2 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 3=Frequently | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 0=None | 1 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 1=Mild | 4 | 4 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 2=Moderate | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 3=Severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 4=Very severe | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 0=Never | 0 | 3 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 1=Rarely | 4 | 3 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 2=Occasionally | 1 | 1 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 3=Frequently | 0 | 0 |
| Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 0=None | — | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 1=Mild | — | 1 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 2=Moderate | — | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 3=Severe | — | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 4=Very severe | — | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 0=Never | 2 | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 1=Rarely | 0 | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 2=Occasionally | 0 | 1 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 3=Frequently | 0 | 0 |
| Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 4=Almost constantly | 0 | 0 |
| Sad or Unhappy Feelings, End Of Treatment, Severity, 0=None | — | 1 |
| Sad or Unhappy Feelings, End Of Treatment, Severity, 1=Mild | — | 1 |
| Sad or Unhappy Feelings, End Of Treatment, Severity, 2=Moderate | — | 0 |
| Sad or Unhappy Feelings, End Of Treatment, Severity, 3=Severe | — | 0 |
| Sad or Unhappy Feelings, End Of Treatment, Severity, 4=Very severe | — | 0 |
| Sad or Unhappy Feelings, End Of Treatment, Frequency, 0=Never | — | 3 |
| Sad or Unhappy Feelings, End Of Treatment, Frequency, 1=Rarely | — | 2 |
| Sad or Unhappy Feelings, End Of Treatment, Frequency, 2=Occasionally | — | 0 |
| Sad or Unhappy Feelings, End Of Treatment, Frequency, 3=Frequently | — | 0 |
| Sad or Unhappy Feelings, End Of Treatment, Frequency, 4=Almost constantly | — | 0 |
The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for participants with cancer. It evaluates the extent to which side effects of treatment are bothersome for cancer participants. This outcome is measured using a 5-category response scale, where responses include 0="Not at all," 1="A little bit," 2="Somewhat," 3="Quite a bit," and 4="Very much." A higher score on this measure indicates that the participant experiences a greater level of bother from the side effects of treatment.
| Participants | Platinum-taxane | Niraparib |
|---|---|---|
| Baseline, 0=Not at all | 4 | 4 |
| Baseline, 1=A little bit | 4 | 6 |
| Baseline, 2=Somewhat | 1 | 7 |
| Baseline, 3=Quite a bit | 4 | 0 |
| Baseline, 4=Very much | 1 | 0 |
| Cycle 1 Day 8, 0=Not at all | 0 | 2 |
| Cycle 1 Day 8, 1=A little bit | 2 | 5 |
| Cycle 1 Day 8, 2=Somewhat | 2 | 7 |
| Cycle 1 Day 8, 3=Quite a bit | 6 | 1 |
| Cycle 1 Day 8, 4=Very much | 1 | 0 |
| Cycle 1 Day 15, 0=Not at all | 4 | 5 |
| Cycle 1 Day 15, 1=A little bit | 2 | 2 |
| Cycle 1 Day 15, 2=Somewhat | 4 | 7 |
| Cycle 1 Day 15, 3=Quite a bit | 2 | 0 |
| Cycle 1 Day 15, 4=Very much | 2 | 0 |
| Cycle 2 Day 1, 0=Not at all | 4 | 5 |
| Cycle 2 Day 1, 1=A little bit | 4 | 2 |
| Cycle 2 Day 1, 2=Somewhat | 2 | 5 |
| Cycle 2 Day 1, 3=Quite a bit | 1 | 2 |
| Cycle 2 Day 1, 4=Very much | 0 | 0 |
| Cycle 2 Day 8, 0=Not at all | 1 | 3 |
| Cycle 2 Day 8, 1=A little bit | 4 | 3 |
| Cycle 2 Day 8, 2=Somewhat | 3 | 6 |
| Cycle 2 Day 8, 3=Quite a bit | 1 | 0 |
| Cycle 2 Day 8, 4=Very much | 2 | 0 |
| Cycle 2 Day 15, 0=Not at all | 2 | 4 |
| Cycle 2 Day 15, 1=A little bit | 3 | 5 |
| Cycle 2 Day 15, 2=Somewhat | 5 | 4 |
| Cycle 2 Day 15, 3=Quite a bit | 2 | 1 |
| Cycle 2 Day 15, 4=Very much | 1 | 0 |
| Cycle 3 Day 1, 0=Not at all | 1 | 4 |
| Cycle 3 Day 1, 1=A little bit | 9 | 3 |
| Cycle 3 Day 1, 2=Somewhat | 4 | 6 |
| Cycle 3 Day 1, 3=Quite a bit | 0 | 1 |
| Cycle 3 Day 1, 4=Very much | 0 | 0 |
| Cycle 3 Day 8, 0=Not at all | 1 | 1 |
| Cycle 3 Day 8, 1=A little bit | 3 | 3 |
| Cycle 3 Day 8, 2=Somewhat | 0 | 6 |
| Cycle 3 Day 8, 3=Quite a bit | 5 | 0 |
| Cycle 3 Day 8, 4=Very much | 1 | 0 |
| Cycle 3 Day 15, 0=Not at all | 0 | 2 |
| Cycle 3 Day 15, 1=A little bit | 3 | 2 |
| Cycle 3 Day 15, 2=Somewhat | 1 | 3 |
| Cycle 3 Day 15, 3=Quite a bit | 1 | 0 |
| Cycle 3 Day 15, 4=Very much | 0 | 0 |
| Pre-IDS Evaluation, 0=Not at all | 2 | 2 |
| Pre-IDS Evaluation, 1=A little bit | 7 | 1 |
| Pre-IDS Evaluation, 2=Somewhat | 6 | 4 |
| Pre-IDS Evaluation, 3=Quite a bit | 0 | 0 |
| Pre-IDS Evaluation, 4=Very much | 0 | 0 |
| End Of Treatment, 0=Not at all | — | 2 |
| End Of Treatment, 1=A little bit | — | 1 |
| End Of Treatment, 2=Somewhat | — | 2 |
| End Of Treatment, 3=Quite a bit | — | 0 |
| End Of Treatment, 4=Very much | — | 0 |
EORTC IL136 includes items from the EORTC QLQ-C30, a 30-item survey assessing health-related quality of life (HRQoL) in cancer patients, featuring 5 functional scales, 3 symptom scales, 6 single items, and a global health status/HRQoL scale. Functional and symptom scales/items are rated on 4-point scale with options "Not at all," "A little," "Quite a bit," and "Very much". 2 items measuring global health status/quality of life use a 7-point scale ranging from 1 ("Very Poor") to 7 ("Excellent"). Each item has a specific scoring system, and scores were transformed to a 0-100 scale, where higher scores on functional scales and global health status/HRQoL scale indicate better functioning or quality of life, while higher scores on symptom scales/items indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to Cycle 1 Day 1 (C1D1), including those from unscheduled visits.
| Scores on scale | Platinum-taxane | Niraparib |
|---|---|---|
| Global Health Status/QoL, CFB to CYCLE 2 DAY 1 | 0.00 ± 19.365 | 3.79 ± 27.224 |
| Global Health Status/QoL, CFB to CYCLE 3 DAY 1 | 7.64 ± 16.460 | 10.19 ± 38.814 |
| Global Health Status/QoL, CFB to Pre-IDS EVALUATION | -4.17 ± 22.349 | 9.72 ± 27.597 |
| Global Health Status/QoL, CFB to END OF TREATMENT | — | -23.33 ± 23.863 |
| Rate Your Overall Health, CFB to CYCLE 2 DAY 1 | -1.52 ± 22.918 | 4.55 ± 27.979 |
| Rate Your Overall Health, CFB to CYCLE 3 DAY 1 | 9.72 ± 16.603 | 9.26 ± 40.062 |
| Rate Your Overall Health, CFB to Pre-IDS EVALUATION | -4.76 ± 23.956 | 11.11 ± 29.187 |
| Rate Your Overall Health, CFB to END OF TREATMENT | — | -20.00 ± 18.257 |
| Rate Your Overall Quality of Life, CFB to CYCLE 2 DAY 1 | 1.52 ± 18.936 | 3.03 ± 28.692 |
| Rate Your Overall Quality of Life, CFB to CYCLE 3 DAY 1 | 5.56 ± 19.245 | 11.11 ± 38.188 |
| Rate Your Overall Quality of Life, CFB to Pre-IDS EVALUATION | -3.57 ± 21.857 | 8.33 ± 27.386 |
| Rate Your Overall Quality of Life, CFB to END OF TREATMENT | — | -26.67 ± 32.489 |
| Physical Functioning Scale, CFB to CYCLE 2 DAY 1 | 0.61 ± 13.150 | 7.27 ± 12.808 |
| Physical Functioning Scale, CFB to CYCLE 3 DAY 1 | 1.53 ± 12.702 | 10.37 ± 16.025 |
| Physical Functioning Scale, CFB to Pre-IDS EVALUATION | -1.43 ± 10.838 | 14.44 ± 20.403 |
| Physical Functioning Scale, CFB to END OF TREATMENT | — | -9.33 ± 17.385 |
| Trouble Doing Strenuous Activity, CFB to CYCLE 2 DAY 1 | 0.00 ± 21.082 | 3.03 ± 27.707 |
| Trouble Doing Strenuous Activity, CFB to CYCLE 3 DAY 1 | -2.78 ± 9.623 | 22.22 ± 23.570 |
| Trouble Doing Strenuous Activity, CFB to Pre-IDS EVALUATION | -7.14 ± 19.298 | 22.22 ± 34.427 |
| Trouble Doing Strenuous Activity, CFB to END OF TREATMENT | — | 0.00 ± 33.333 |
| Have Trouble Taking a Long Walk, CFB to CYCLE 2 DAY 1 | 0.00 ± 21.082 | 21.21 ± 30.814 |
| Have Trouble Taking a Long Walk, CFB to CYCLE 3 DAY 1 | 13.89 ± 30.011 | 11.11 ± 28.868 |
| Have Trouble Taking a Long Walk, CFB to Pre-IDS EVALUATION | 4.76 ± 22.100 | 22.22 ± 34.427 |
| Have Trouble Taking a Long Walk, CFB to END OF TREATMENT | — | -6.67 ± 14.907 |
| Have Trouble Taking Short Walk, CFB to CYCLE 2 DAY 1 | 6.06 ± 20.101 | 9.09 ± 15.570 |
| Have Trouble Taking Short Walk, CFB to CYCLE 3 DAY 1 | 0.00 ± 33.333 | 7.41 ± 14.699 |
| Have Trouble Taking Short Walk, CFB to Pre-IDS EVALUATION | -4.76 ± 17.817 | 16.67 ± 27.889 |
| Have Trouble Taking Short Walk, CFB to END OF TREATMENT | — | -13.33 ± 18.257 |
| Stay in Bed or Chair During Day, CFB to CYCLE 2 DAY 1 | -3.03 ± 17.979 | 0.00 ± 25.820 |
| Stay in Bed or Chair During Day, CFB to CYCLE 3 DAY 1 | -2.78 ± 22.285 | 7.41 ± 22.222 |
| Stay in Bed or Chair During Day, CFB to Pre-IDS EVALUATION | 0.00 ± 18.490 | 0.00 ± 21.082 |
| Stay in Bed or Chair During Day, CFB to END OF TREATMENT | — | -13.33 ± 18.257 |
| Need Help Eating Dressing Washing, CFB to CYCLE 2 DAY 1 | 0.00 ± 0.000 | 3.03 ± 17.979 |
| Need Help Eating Dressing Washing, CFB to CYCLE 3 DAY 1 | 0.00 ± 0.000 | 3.70 ± 20.031 |
| Need Help Eating Dressing Washing, CFB to Pre-IDS EVALUATION | 0.00 ± 0.000 | 11.11 ± 17.213 |
| Need Help Eating Dressing Washing, CFB to END OF TREATMENT | — | -13.33 ± 18.257 |
| Social Functioning Scale, CFB to CYCLE 2 DAY 1 | 13.64 ± 27.707 | 7.58 ± 36.027 |
| Social Functioning Scale, CFB to CYCLE 3 DAY 1 | 13.89 ± 30.841 | 1.85 ± 22.737 |
| Social Functioning Scale, CFB to Pre-IDS EVALUATION | 7.14 ± 27.514 | 8.33 ± 25.276 |
| Social Functioning Scale, CFB to END OF TREATMENT | — | 3.33 ± 18.257 |
| Cond Interfere With Family Life, CFB to CYCLE 2 DAY 1 | 18.18 ± 31.140 | 6.06 ± 44.267 |
| Cond Interfere With Family Life, CFB to CYCLE 3 DAY 1 | 13.89 ± 33.207 | -7.41 ± 27.778 |
| Cond Interfere With Family Life, CFB to Pre-IDS EVALUATION | 14.29 ± 36.314 | -5.56 ± 38.968 |
| Cond Interfere With Family Life, CFB to END OF TREATMENT | — | -6.67 ± 27.889 |
| Cond Interfere Social Activity, CFB to CYCLE 2 DAY 1 | 9.09 ± 30.151 | 9.09 ± 33.635 |
| Cond Interfere Social Activity, CFB to CYCLE 3 DAY 1 | 13.89 ± 30.011 | 11.11 ± 28.868 |
| Cond Interfere Social Activity, CFB to Pre-IDS EVALUATION | 0.00 ± 26.149 | 22.22 ± 17.213 |
| Cond Interfere Social Activity, CFB to END OF TREATMENT | — | 13.33 ± 18.257 |
| Dyspnea Symptom Scale, CFB to CYCLE 2 DAY 1 | -3.03 ± 10.050 | 3.03 ± 17.979 |
| Dyspnea Symptom Scale, CFB to CYCLE 3 DAY 1 | 0.00 ± 14.213 | 0.00 ± 28.868 |
| Dyspnea Symptom Scale, CFB to Pre-IDS EVALUATION | 0.00 ± 13.074 | 0.00 ± 47.140 |
| Dyspnea Symptom Scale, CFB to END OF TREATMENT | — | 6.67 ± 27.889 |
| Were You Short of Breath, CFB to CYCLE 2 DAY 1 | -3.03 ± 10.050 | 3.03 ± 17.979 |
| Were You Short of Breath, CFB to CYCLE 3 DAY 1 | 0.00 ± 14.213 | 0.00 ± 28.868 |
| Were You Short of Breath, CFB to Pre-IDS EVALUATION | 0.00 ± 13.074 | 0.00 ± 47.140 |
| Were You Short of Breath, CFB to END OF TREATMENT | — | 6.67 ± 27.889 |
The OC module (QLQ-OV28) supplements the QLQ-C30 and was designed for participants with local or advanced disease who receive treatment by surgery with or without chemotherapy. It consists of 28 items including 3 functional scales (body image, sexuality, attitude to disease/treatment burden) and 5 symptom scales/items (abdominal/gastrointestinal symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side effects, and hair loss). A subset of 9 questions will be utilized for this cohort, referred to as the EORTC IL137. The scoring approach is identical to the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, where higher functional scale scores indicate better functioning, and higher symptom scale scores indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to C1D1, including unscheduled visits.
| Scores on scale | Platinum-taxane | Niraparib |
|---|---|---|
| Felt physically Less Attractive, CFB to CYCLE 2 DAY 1 | -2.78 ± 17.164 | -3.33 ± 33.148 |
| Felt physically Less Attractive, CFB to CYCLE 3 DAY 1 | -2.78 ± 33.207 | 7.41 ± 52.116 |
| Felt physically Less Attractive, CFB to Pre-IDS EVALUATION | 0.00 ± 18.490 | -16.67 ± 27.889 |
| Felt physically Less Attractive, CFB to END OF TREATMENT | — | 13.33 ± 38.006 |
| Disease Burden, CFB to CYCLE 2 DAY 1 | 5.56 ± 19.245 | 10.00 ± 27.442 |
| Disease Burden, CFB to CYCLE 3 DAY 1 | 11.11 ± 25.950 | 14.81 ± 50.308 |
| Disease Burden, CFB to Pre-IDS EVALUATION | 11.90 ± 24.832 | 0.00 ± 42.164 |
| Disease Burden, CFB to END OF TREATMENT | — | 13.33 ± 44.721 |
| Treatment Burden, CFB to CYCLE 2 DAY 1 | -8.33 ± 32.177 | 3.33 ± 39.907 |
| Treatment Burden, CFB to CYCLE 3 DAY 1 | 0.00 ± 24.618 | 7.41 ± 32.394 |
| Treatment Burden, CFB to Pre-IDS EVALUATION | 2.38 ± 27.625 | 11.11 ± 27.217 |
| Treatment Burden, CFB to END OF TREATMENT | — | 13.33 ± 18.257 |
| Bloated Feeling Abdomen, CFB to CYCLE 2 DAY 1 | -8.33 ± 35.176 | -10.00 ± 41.722 |
| Bloated Feeling Abdomen, CFB to CYCLE 3 DAY 1 | 0.00 ± 42.640 | -14.81 ± 29.397 |
| Bloated Feeling Abdomen, CFB to Pre-IDS EVALUATION | 0.00 ± 29.235 | -5.56 ± 49.065 |
| Bloated Feeling Abdomen, CFB to END OF TREATMENT | — | 6.67 ± 43.461 |
| Change Bowel Habit, CFB to CYCLE 2 DAY 1 | -33.33 ± 34.816 | 0.00 ± 41.574 |
| Change Bowel Habit, CFB to CYCLE 3 DAY 1 | -13.89 ± 45.965 | -7.41 ± 22.222 |
| Change Bowel Habit, CFB to Pre-IDS EVALUATION | -16.67 ± 31.351 | -11.11 ± 40.369 |
| Change Bowel Habit, CFB to END OF TREATMENT | — | -6.67 ± 14.907 |
| Troubled Pass Flatulence, CFB to CYCLE 2 DAY 1 | 8.33 ± 25.126 | -3.33 ± 24.595 |
| Troubled Pass Flatulence, CFB to CYCLE 3 DAY 1 | -2.78 ± 22.285 | -3.70 ± 35.136 |
| Troubled Pass Flatulence, CFB to Pre-IDS EVALUATION | 7.14 ± 26.726 | 0.00 ± 29.814 |
| Troubled Pass Flatulence, CFB to END OF TREATMENT | — | -20.00 ± 29.814 |
| Felt Full Quick after Begin Eat, CFB to CYCLE 2 DAY 1 | -13.89 ± 22.285 | 0.00 ± 41.574 |
| Felt Full Quick after Begin Eat, CFB to CYCLE 3 DAY 1 | -15.15 ± 22.918 | -14.81 ± 33.793 |
| Felt Full Quick after Begin Eat, CFB to Pre-IDS EVALUATION | -11.90 ± 28.063 | 5.56 ± 25.092 |
| Felt Full Quick after Begin Eat, CFB to END OF TREATMENT | — | -6.67 ± 59.628 |
| Acid Indigestion or Heartburn, CFB to CYCLE 2 DAY 1 | 2.78 ± 17.164 | -3.33 ± 29.187 |
| Acid Indigestion or Heartburn, CFB to CYCLE 3 DAY 1 | 5.56 ± 12.975 | -7.41 ± 32.394 |
| Acid Indigestion or Heartburn, CFB to Pre-IDS EVALUATION | 7.14 ± 14.194 | -11.11 ± 27.217 |
| Acid Indigestion or Heartburn, CFB to END OF TREATMENT | — | 6.67 ± 27.889 |
| Felt Weak in Your Arms or Legs, CFB to CYCLE 2 DAY 1 | -5.56 ± 19.245 | -6.67 ± 21.082 |
| Felt Weak in Your Arms or Legs, CFB to CYCLE 3 DAY 1 | 18.18 ± 34.524 | -18.52 ± 33.793 |
| Felt Weak in Your Arms or Legs, CFB to Pre-IDS EVALUATION | 4.76 ± 34.237 | -11.11 ± 34.427 |
| Felt Weak in Your Arms or Legs, CFB to END OF TREATMENT | — | 6.67 ± 27.889 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Platinum-taxane | Niraparib |
|---|---|---|
| TE Non-SAEs | 17 | 19 |
| TESAEs | 4 | 2 |
| TE AESIs | 0 | 0 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with dose modifications : permanent discontinuation, dose reduction and treatment interruption/delay due to AEs is summarized.
| Participants | Platinum-taxane | Niraparib |
|---|---|---|
| Permanent Discontinuation | 5 | 4 |
| Dose Reduction | 14 | 7 |
| Treatment Interruption/delay | 11 | 11 |
Collected over All-cause mortality, Treatment-Emergent Serious Adverse Events (TESAEs), and TE Non-SAEs were collected up to approximately 154 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Platinum-taxane | 4/17 (23.5%) | 4/17 (23.5%) | 17/17 (100%) |
| Niraparib | 4/19 (21.1%) | 2/19 (10.5%) | 19/19 (100%) |
| Event | Platinum-taxane | Niraparib |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 2/17 | 0/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/17 | 0/19 |
| Cardiac failureCardiac disorders | 1/17 | 0/19 |
| Large intestine perforationGastrointestinal disorders | 1/17 | 0/19 |
| General physical health deteriorationGeneral disorders | 1/17 | 0/19 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/17 | 0/19 |
| Pelvic haematomaReproductive system and breast disorders | 1/17 | 0/19 |
| HypotensionVascular disorders | 1/17 | 0/19 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/17 | 1/19 |
| Haemorrhagic strokeNervous system disorders | 0/17 | 1/19 |
| Event | Platinum-taxane | Niraparib |
|---|---|---|
| FatigueGeneral disorders | 14/17 | 7/19 |
| Neuropathy peripheralNervous system disorders | 13/17 | 1/19 |
| AnaemiaBlood and lymphatic system disorders | 11/17 | 10/19 |
| NauseaGastrointestinal disorders | 11/17 | 4/19 |
| ConstipationGastrointestinal disorders | 10/17 | 8/19 |
| InsomniaPsychiatric disorders | 8/17 | 9/19 |
| NeutropeniaBlood and lymphatic system disorders | 8/17 | 3/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/17 | 5/19 |
| Abdominal painGastrointestinal disorders | 8/17 | 6/19 |
| VomitingGastrointestinal disorders | 8/17 | 4/19 |
| Age, Continuous(YEARS) | Platinum-taxane | Niraparib | Total |
|---|---|---|---|
| Mean | 61.0 ± 13.67 | 58.4 ± 12.26 | 59.6 ± 12.82 |
| Sex: Female, Male(Participants) | Platinum-taxane | Niraparib | Total |
|---|---|---|---|
| Female | 17 | 19 | 36 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Platinum-taxane | Niraparib | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 16 | 16 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Apr 2022 to primary completion in Jun 2024, 26 months.
Results were first posted in Jul 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niraparib · Carboplatin · Paclitaxel